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Abstract: The quinolones trap DNA gyrase and DNA topoisomerase IV on DNA as complexes in which the DNA is 
broken but constrained by protein. Early studies suggested that drug binding occurs largely along helix-4 of the GyrA 
(gyrase) and ParC (topoisomerase IV) proteins. However, recent X-ray crystallography shows drug intercalating between 
the -1 and +1 nucleotides of cut DNA, with only one end of the drug extending to helix-4. These two models may reflect 
distinct structural steps in complex formation. A consequence of drug-enzyme-DNA complex formation is reversible 
inhibition of DNA replication; cell death arises from subsequent events in which bacterial chromosomes are fragmented 
through two poorly understood pathways. In one pathway, chromosome fragmentation stimulates excessive accumulation 
of highly toxic reactive oxygen species that are responsible for cell death. Quinolone resistance arises stepwise through 
selective amplification of mutants when drug concentrations are above the MIC and below the MPC, as observed with 
static agar plate assays, dynamic in vitro systems, and experimental infection of rabbits. The gap between MIC and MPC 
can be narrowed by compound design that should restrict the emergence of resistance. Resistance is likely to become 
increasingly important, since three types of plasmid-borne resistance have been reported. 
INTRODUCTION 
  The quinolones are broad-spectrum antibacterial agents 
that are receiving increasing attention as resistance develops 
to other compounds. Unfortunately, the quinolones are also 
losing their utility due to bacterial resistance, which creates a 
sense of urgency to develop new, more effective derivatives. 
As a result, biochemical insights continue to emerge, and we 
can now begin to discuss crystal structures of drug-target-
DNA complexes. Our understanding of intracellular 
quinolone action is also deepening. For example, evidence is 
accumulating that lethal action is due to chromosome 
fragmentation and the resulting surge in reactive oxygen 
species (ROS). While finding new quinolone derivatives has 
continued along conventional lines that seek low MIC, that 
effort is expanding to include identification of compounds 
having good activity with mutants resistant to existing 
compounds. We expect studies with fluoroquinolone resis-
tance to eventually lead regulatory agencies to add anti-
mutant properties to the evaluation of new compounds. 
These and other developments make an update of quinolone 
action and resistance timely.  
  We use the term quinolone in a generic sense that refers 
loosely to a class of inhibitors that includes naphthyridones, 
quinolones, quinazolines, isothiazoloquinolones, and related 
agents. These compounds have as their targets two essential 
bacterial enzymes, DNA gyrase (topoisomerase II) [1] and 
DNA topoisomerase IV [2]. The two enzymes, each of 
which contains 4 subunits (2 GyrA or ParC and 2 GyrB or  
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ParE), act by passing one region of duplex DNA through 
another [3-6]; during that process, the quinolones form 
complexes with enzyme and DNA [1, 7]. The DNA moiety 
in the complex is broken, as revealed by detection of frag-
mented DNA following addition of protease, ionic detergent 
(sodium dodecyl sulfate, SDS), or both to quinolone-
containing reaction mixtures or lysates from quinolone-
treated bacterial cells [1, 7, 8]. The complexes are called 
“cleaved” or “cleavable” to indicate the presence of broken 
DNA that is covalently attached to the enzyme at the 5’ ends. 
Chromosomal DNA remains supercoiled when obtained 
from cells treated with quinolones at bacteriostatic concen-
trations, provided that the complexes are kept intact by 
omission of protein denaturants from cell lysis procedures 
[8]. The presence of supercoils indicates that the DNA 
breaks in the complexes are constrained in a way that 
prevents the rotation of DNA ends that would otherwise 
relax supercoils. However, when cells are treated with lethal 
drug concentrations, the supercoils are absent, indicating 
release of the DNA ends from the complexes. That release is 
expected to fragment chromosomes. 
  The hallmark of quinolone action is formation of cleaved 
complexes.  In vitro, the complexes block movement of 
replication forks and transcription complexes, thereby 
inhibiting bacterial growth [9-11]. Lethal action arises at 
higher quinolone concentrations in parallel with chromo-
some fragmentation. Thus, bacteriostatic action and rapid 
lethal effects are distinct. By normalizing lethal action to 
MIC, it is possible to minimize the contribution of factors, 
such as drug uptake and efflux, that would otherwise 
confound comparison of quinolones during studies of drug 
mechanism. 
  Cleaved complexes are also important for quinolone 
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fere with drug binding [12]. However, quinolone resistance 
also arises from mutations that alter drug uptake, efflux, and 
structure [13-17]. Many of these mutations do not by them-
selves provide clinical resistance, but they may facilitate the 
stepwise accumulation of additional mutations [13, 18, 19]. 
Stepwise resistance distinguishes the emergence of 
quinolone resistance from the all-or-none phenomenon seen 
for rifampicin with Escherichia coli and Staphylococcus 
aureus [20]. It also underlies use of the mutant selection 
window hypothesis as a framework for suppressing the 
emergence of resistance (the hypothesis maintains that 
resistant mutant subpopulations are selectively enriched and 
amplified when drug concentrations fall in a range above the 
MIC for the susceptible population and below the MIC of the 
least susceptible mutant subpopulation, a value called the 
MPC). The selection window can be used to formulate 
dosing regimens, to choose compounds for therapy, and to 
design new agents.  
  Below we turn first to biochemical studies of cleaved 
complex formation. Knowledge gained from crystal 
structures is moving us toward an atomic description of the 
complexes, with current data appearing to require a two-step 
model. An underlying assumption of structural studies is that 
the type II topoisomerases have very similar structures; 
consequently, conclusions drawn with one enzyme are often 
applied to others. While this assumption is generally sound, 
the enzymes differ; in the second section we discuss the C-
terminal domains of the GyrA and ParC proteins, regions 
where major differences between gyrase and topoisomerase 
IV appear. We then shift to biological consequences of 
cleaved complex formation: inhibition of DNA replication, 
chromo-some fragmentation, and accumulation of ROS. 
Recent studies of resistance include support for the mutant 
selection window hypothesis and the discovery of new 
quinolone-like compounds that exhibit excellent in vitro 
activity with mutants resistant to existing quinolones. We 
conclude with an update on the three types of plasmid-borne 
fluoroquinolone resistance. Readers interested in earlier 
reviews are referred to [21-27]. 
CRYSTAL STRUCTURES AND MODELS FOR 
CLEAVED COMPLEXES  
  For many years our understanding of quinolone action 
has been based on crystal structures of GyrA fragments [28] 
and eukaryotic topoisomerase II [29]. Such studies describe 
the portion of GyrA and ParC involved with the DNA 
breaks. Most of the attention focused on helix-4 because it is 
the location of amino acid substitutions generally associated 
with quinolone resistance and presumably drug binding. 
Since quinolones were not part of these structures, the work 
revealed little about the positioning of the drugs.  
  When the structure of a co-crystal of yeast topoisomerase 
II and DNA was solved [30], several striking features were 
seen. First, the topoisomerase forces a 150° bend in DNA 
upon binding to the G (gate)-segment of DNA [30]. Second, 
the central four base pairs of the binding site adopt an A-
form conformation, whereas DNA at the outermost edges of 
the G-segment binding site is B-form. Third, large confor-
mational changes of the enzyme take place upon its binding 
to DNA [30], a conclusion that supports earlier biochemical 
work [31]. The conformational change creates a catalytic site 
having a DNA binding surface that extends across both 
protein protamers. This conformation positions the DNA 
backbone near a reactive tyrosine and a coordinated magne-
sium ion thought to be part of the DNA cleavage reaction.  
  Covariation between C-7-piperazinyl ring substituents 
and susceptibility to particular resistance substitutions 
suggested a drug-binding orientation (Fig. 1). For example, 
with Mycobacterium smegmatis, a fluoroquinolone with a C-
7-piperazinyl-N-linked ethyl moiety was less active against a 
Gly-81 to Cys variant (we use the E. coli numbering system 
for simplicity) than a similar quinolone with a C-linked ethyl 
[32]; amino acid substitutions at other positions in helix-4 
failed to distinguish between the compounds. Since position 
81 is located at the N-terminus of helix-4, the idea arose that 
the C-7-distal end of the quinolone binds near the N-
terminus of the helix. According to this hypothesis, the other 
(keto-carboxy) end of the quinolone would bind near amino 
acid positions 83 and 87, two positions where major 
resistance substitutions map. As a further test of this idea, we 
recently constructed a C-7 piperazinyl N-bromoacetyl 
derivative of ciprofloxacin (Cip-Br) that has intracellular 
properties consistent with crosslinking to Cys-81 (low MIC 
and irreversibility of inhibition of DNA synthesis that are 
specific to Cys-81 and the bromo compound; A.M. and 
M.M., unpublished observations). Our data are consistent 
with binding of quinolones to multiple points along helix-4 
with the C-7 ring near position 81 (Fig. 1). 
  A very different idea for drug binding recently arose 
from a crystal structure of a cleaved complex composed of 
the DNA-binding core of Streptococcus pneumoniae 
topoisomerase IV complexed with broken DNA and either 
clinafloxacin (Fig. 2A) or moxifloxacin [33]. In this model, 
each fluoroquinolone molecule intercalates in the gap 
between the -1 and +1 nucleotide pairs of the cleaved DNA 
bound to the symmetrical topoisomerase IV heterodimer 
(Fig.  2B shows binding of one clinafloxacin molecule). 
Interaction with the -1 nucleotide is consistent with the 
observation that an abasic site at the -1 position inhibits 
formation of quinolone-induced cleaved complex at the site 
(HH, unpublished observations). A characteristic feature of 
the DNA intercalation model is the interaction of the C-7 
substituent of the quinolone with DNA base pairs rather than 
with amino acid 81, which is far from the DNA moiety.  
  In the DNA intercalation model (Fig. 2B), the 3-carboxyl 
group of the fluoroquinolone rests on a platform composed 
of the amino terminus of helix-4 such that the 3-carboxyl 
contacts Ser-79 (position 83 in E. coli GyrA) and is in close 
proximity to Ser-80 (Ala-84 of GyrA). The carboxyl group 
of Asp-78 (82 in GyrA) is not resolved in the structure, but it 
may be close enough to the 3-carboxyl group of the 
fluoroquinolone to allow formation of a Mg
2+ bridge, which 
has been suggested to be important for drug binding due to 
the Mg
+2-dependence of complex formation and reversal of 
DNA cleavage by EDTA [7]. Alternatively, the 3-carboxyl 
may participate in an electrostatic interaction with the 
guanidine group of Arg-118 (GyrA 121), which is also 
unresolved in the structure. Finally, one of the hydrogen 
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gen bond with the 4-keto group of the drug, which would 
strengthen binding. 
  The DNA intercalation model shows how drug binding 
could prevent the religation of DNA. It also explains the 
protective effect of some resistance mutations. For example, 
a substitution at Asp-78 (GyrA 82) would eliminate a 
putative Mg
2+ bridge, thereby weakening drug binding; 
substitution at Gly-77 (GyrA 81) could introduce a bulky 
side chain that would sterically clash with the oxygen of the 
fluoroquinolone 3-carboxyl group and/or push away the side 
chain of Arg-118, thereby interfering with interaction of this 
residue with the fluoroquinolone. The close proximity of 
Arg-118 (GyrA 121) to the fluoroquinolone 3-carboxyl 
group suggests that an interaction there might be significant 
to drug binding, which should be reflected in the recovery of 
resistance substitutions. Such mutations are not common, 
perhaps due to the importance of the arginine residue for 
catalysis (this amino acid is highly conserved among type II 
topoisomerases). Substitutions of Ser-79 (GyrA 83), as well 
as those at position 80 (GyrA 84), are expected to reposition 
the drug molecule, thereby affecting other fluoroquinolone-
protein interactions. The DNA intercalation model is also 
consistent with the protective effect of ParE substitutions at 
amino acids 435 (GyrB 426) and 456 (GyrB 447), which are 
located close to the bound drug.  
  The effects of several amino acid substitutions and drug 
structure variations are unexplained by the DNA inter-
calation model. One example is the putative interaction of 
the C-7 substituent with position 81, as noted above. Another 
is substitution at position 83 (GyrA 87), which is highly 
protective from quinolone action. In the model, GyrA-87 
substitutions are too far from the fluoroquinolone-binding 
site to interfere with drug action. The model also fails to 
explain effects of drug substituents at positions 1 and 8 that 
significantly alter both the antimicrobial activity and the 
drug-target binding constant [34]: in the X-ray structure, the 
moieties at positions 1 and 8 make no contact with either 
DNA or protein. In particular, the (-) isomer of ofloxacin 
(levofloxacin) binds to bacterial  gyrase about 10-12 times 
more efficiently than the (+) isomer [35], but modeling of 
ofloxacin onto the DNA intercalation structure provides no 
insight into the effects of the isomers. In addition, the role of 
the fluorine substitution at position 6, which significantly 
improves antibacterial activity, remains obscure. Laponogov 
et al. [33] suggest that the C-6 fluorine might influence 
charge distribution to favor stacking interactions with DNA 
bases. Finally, the protective effect of a substitution at Gly-
77 (GyrA 81) for fluoroquinolones but not nalidixic acid 
[36] remains unexplained, as does the effect of the Cip-Br 
derivative when Cys is substituted for Gly at position 81. 
The latter is particularly problematic, since the DNA inter-
calation model asserts that the C-7 piperazinyl ring, which 
we suggest can be crosslinked to GyrA Cys-81, stacks with 
DNA bases. 
  One way to accommodate the genetic-drug structure data 
described above with the intercalation model is to postulate 
that quinolone binding is a multi-step process involving 
structures in which drug binding is quite different. Indeed, 
quinolone binding is known to involve at least two steps, one 
that occurs before DNA cleavage and one that occurs after 
[37, 38]. Thus, Figs. 1 and 2 may describe two different 
steps in cleaved complex formation.  
DIFFERENCES BETWEEN THE CARBOXYL-
TERMINAL DOMAINS OF GYRA AND PARC 
  The two molecular targets of the quinolones, DNA 
gyrase and DNA topoisomerase IV, are homologous, and 
many interactions with quinolones are very similar for the 
two enzymes [25]. Indeed, all of the type II topoisomerases, 
except for topoisomerase VI of Sulfolobus shibatae, are 
highly conserved [21, 27]. However, each enzyme also 
exhibits a distinct catalytic preference that reflects its 
specialized intracellular function. For example, DNA gyrase 
is the only enzyme that can introduce negative supercoils 
into DNA, whereas topoisomerase IV relaxes negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Helix-4 quinolone-binding model. The DNA-gate region is shown for a GyrA-GyrA dimer to which one fluoroquinolone molecule 
is bound such that the distal end of the C-7 ring (C7 tail) is near GyrA position 81 of one GyrA subunit; carboxyl and keto oxygens are near 
GyrA positions 87 and 83, respectively, of the other subunit. 984    Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11  Drlica et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). DNA intercalation model for quinolone binding derived from clinafloxacin-topoisomerase IV-DNA crystallography. Panel A. Space-
filling model for clinafloxacin. Panel B. Relative arrangement of one clinafloxacin molecule, cleaved DNA, and portions of topoisomerase IV 
in the co-crystal structure described by [33]. Panel C. Relative arrangement of two clinafloxacin molecules, cleaved DNA, and portions of 
topoisomerase IV in co-crystal structure described by [33]. Protein and DNA residues in immediate contact with, or in close proximity to FQ 
are indicated (ball & stick representation). ParC features (helixes III, IV) are shown in beige; a short region of ParE (maroon) shows location 
of ParE resistance substitutions. DNA residues flanking the drug molecules are shown in a stick representation (top strand, blue; bottom 
strand, magenta). Quinolones: action and resistance updated  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11     985 
supercoils [39] and decatenates and unknots DNA [40-42]. 
The binding of topoisomerase IV to the G-segment DNA 
takes place only at the amino-terminal catalytic domain 
(NTD) of the ParC subunit, whereas GyrA binds to the G-
segment at both its NTD and its carboxy-terminal domain 
(CTD). Binding at the CTD is thought to wrap the G-
segment DNA around gyrase, thereby enabling the enzyme 
to catalyze DNA supercoiling [43, 44]. Thus, knowledge of 
CTD structure and function is important for understanding 
differences between gyrase and topoisomerase IV. 
  Recent structural studies show that a 35-kDa fragment of 
the CTD of Borrelia burgdorferi GyrA adopts a 6-bladed ‘-
pinwheel’ fold that is reminiscent of the ‘-propeller’ fold 
[45]. Three other CTDs, the Bacillus stearothermophilus 
ParC CTD [46], the Escherichia coli GyrA CTD [47], and 
the  E. coli ParC CTD [48], also adopt a -pinwheel fold. 
While all GyrA CTDs possess 6 blades, ParC CTDs exhibit 
significant structural diversity [45, 48]: some ParC CTDs, 
such as that from B. stearothermophilus, adopt a 6-bladed -
pinwheel fold, whereas others, such as the E. coli ParC CTD, 
adopt a 5-bladed fold. Interestingly, the B. stearothermo-
philus ParC CTD superimposes well on the E. coli GyrA 
CTD [48, 47]. These structural studies of GyrA and ParC 
CTDs, together with phylogenetic data on gyrases and 
topoisomerase IVs, lead to a new picture of how bacterial 
type II topoisomerases are likely to have evolved [45, 48]. 
Gyrase had been considered to be a specialized enzyme that 
had evolved primarily to supercoil DNA [21, 27]. However, 
the specialized function of topoisomerase IV, incremental 
changes observed in the ParC proteins, and a wider distri-
bution and greater conservation of GyrA than ParC, suggest 
that ParC CTDs are degenerate forms of the GyrA CTD and 
that topoisomerase IV evolved from gyrase [48]. The same 
conclusion is also reached by comparing GyrA and ParC 
NTDs [49]. 
  Amino acid sequence alignment, supplemented with 
secondary structure predictions, reveals that the 7-amino-
acid-long GyrA box, QRRGGKG [50], is the only motif 
unique to the GyrA CTD [45, 48]. Either deletion or alanine 
substitution in the GyrA box abolishes the ability of gyrase 
to wrap DNA around itself and to catalyze DNA 
supercoiling [51]. However, these mutations do not affect the 
relaxing and decatenating activities of gyrase. Thus, the 
GyrA box is essential for the unique (supercoiling) activity 
of gyrase. 
  The GyrA CTD, which is joined to the GyrA NTD 
through a flexible linker, moves between upper and lower 
positions during the catalytic cycle [52, 53]. The binding of 
the GyrA box to G-segment DNA may coordinate both the 
position of the GyrA CTD and the direction of G-segment 
DNA bending to allow gyrase to wrap DNA for the 
supercoiling reaction [51]. In contrast, the E. coli ParC 
protein has an ordered linker between its NTD and CTD, and 
the position of the ParC CTD remains fixed relative to the 
ParC NTD. That prevents the ParC CTD from binding to G-
segment DNA [48]. Instead, the ParC CTD captures an 
incoming T (transfer)-segment DNA to catalyze either 
decatenation or relaxation.  
  As discussed below, the wrapping of DNA turns out to be 
important to the stability of cleaved complexes formed with 
gyrase and the ability of the complexes to block replication 
fork progression [54, 55]. Thus, although the GyrA CTD 
does not directly interact with quinolone, the CTD appears to 
influence drug action. Topoisomerase IV, which does not 
wrap DNA, forms cleaved complexes that are intrinsically 
stable enough to cause replication fork arrest [54, 55].  
BACTERIOSTATIC ACTION OF QUINOLONES 
Replication Fork Arrest by Quinolone-Topoisomerase-
DNA Complexes 
  Rapid inhibition of DNA replication is one of the more 
striking consequences of cleaved complex formation with 
quinolones [8, 56] and with inhibitors of eukaryotic DNA 
topoisomerases [57, 58]. In the case of camptothecin and 
eukaryotic topoisomerase I, collision of replication forks 
with cleaved complexes causes fork breakage and the release 
of lethal DNA breaks [59]. Since topoisomerases share 
general features, the possibility arose that a similar pheno-
menon would occur with quinolones and gyrase/topoiso-
merase IV. Indeed, irreversible collision of replication forks 
with quinolone-mediated complexes was thought to be the 
primary source of cell death [60]. However, other work with 
quinolones indicated that inhibition of replication is 
reversible [56]. Thus, the relationship between inhibition of 
DNA synthesis and cell death required additional 
investigation. 
  Several studies have been performed that clarify 
relationships between cell death and collision of replication 
forks with quinolone-mediated cleaved complexes. In one 
approach, cells were treated in ways that block cell death, 
and then the treatments were assessed for effects on 
quinolone-mediated inhibition of DNA synthesis or growth. 
For example, chloramphenicol and anaerobic growth prevent 
first-generation quinolones from killing E. coli. The former 
has little effect on quinolone-mediated inhibition of DNA 
synthesis [61], and the latter allows quinolones to form 
complexes that block growth, presumably by inhibiting 
replication and transcription [62, 63]. Thus, replication and 
cell death are distinct. Another approach was to block 
replication by means other than quinolone treatment and then 
determine whether the quinolones still kill cells. When such 
an experiment was performed with a temperature-sensitive 
dnaB mutant, stopping replication had little effect on the 
lethal activity of the quinolones [64]. A third approach was 
to reconstitute the collision between replication forks and 
quinolone-containing complexes in vitro and determine 
whether double-strand DNA breaks were generated or 
released [9]. They were not [9]. Consequently, the active 
DNA breakage and reunion activity of either gyrase or 
topoisomerase IV, which is required to arrest replication fork 
progression [9, 10, 54], does not cause the breakage of 
replication forks. Similar conclusions have been reached 
with topoisomerase II-targeting anticancer drugs using both 
in vivo and in vitro systems [65, 66]. We conclude that 
cleaved complexes composed of type II topoisomerases 
block replication fork movement without causing fork brea-
kage and rapid cell death.  
  Since quinolone-induced cleaved complexes contain 
broken DNA, it was reasonable to assume that replication 
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68, 69]. However, with S. aureus only a subset of quinolone-
induced cleaved complexes appears to be physiologically 
competent for quinolone action [70], an observation that led 
us to examine how the stability of quinolone-induced clea-
ved complexes contributes to their ability to block repli-
cation fork movement.  
  One line of investigation showed that S. aureus gyrase 
requires high concentrations of potassium glutamate to wrap 
DNA, catalyze DNA supercoiling, and arrest replication fork 
progression  in vitro [55]. Similar studies using an E. coli 
mutant gyrase that lacks the entire GyrA CTD (GyrA59), 
and thus cannot wrap DNA [43], showed that gyrase-
mediated DNA wrapping is required for replication fork 
arrest [54]. Cleaved complexes formed with GyrA59 gyrase 
are also more sensitive to salt than those formed with the 
wild-type gyrase, and GyrA59 gyrase-quinolone-DNA 
ternary complexes readily disassociate from DNA. Thus, 
wrapping of DNA is required for the formation of gyrase-
containing cleaved complexes that are stable enough to block 
replication fork progression.  
  Topoisomerase IV also forms cleaved complexes that 
arrest replication fork progression [54, 55], but topoiso-
merase IV does not wrap DNA. We found that quinolone-
induced cleaved complexes formed with topoisomerase IV 
are more stable
 than those formed with GyrA59 gyrase [54]. 
Critical differences may exist between the GyrA and ParC 
NTDs with respect to their interactions with DNA and/or
 the 
quinolones in cleaved complexes. Another possibility is that 
the placement of the CTD near the tower domain of GyrA or 
ParC is important for the stability of cleaved complexes. 
Gyrase uses DNA wrapping to position the GyrA CTD near 
the tower domain [52, 53], whereas it is the ordered linker 
between the NTD and the CTD that places the ParC CTD 
near the tower [48].  
  Studies of helix-4 also bear on complex stability. As 
pointed out above, two mutational hotspots for quinolone 
resistance, Ser-83 and Asp-87, locate on GyrA helix-4 [28], 
and similar hotspots are found in analogous regions of ParC 
[22, 68]. Thus, helix-4 is probably a part of the quinolone-
binding site, as pointed out in the crystal structure section 
above. Although DNA-binding domains, including helix-4, 
are highly conserved among gyrases and topoisomerase IVs, 
differences do occur. Swapping helix-4 of E. coli GyrA with 
that of E. coli ParC [71] and swapping an extended region 
around helix-4 of E. coli GyrA with that of S. aureus GyrA 
[72] reveal that subtle differences in amino acid residues in 
and/or around helix-4 affect the quinolone sensitivity of a 
topoisomerase. Furthermore, quinolone-induced cleaved 
complexes formed with a mutant topoisomerase IV con-
taining helix-4 of E. coli GyrA are more sensitive to quino-
lone and more stable than those formed with topoisomerase 
IV; they are less sensitive and less stable than complexes 
formed with gyrase [71]. Thus, quinolone sensitivity of a 
topoisomerase correlates with the stability of the cleaved 
complex. Likewise, cytotoxicity of topoisomerase II-targe-
ting anticancer drugs correlates with the stability of drug-
induced cleaved complexes [73].  
 
 
Double-Strand DNA Breaks Arising from Inhibition of 
Replication 
  While we have argued above that lethal replication fork 
breakage does not arise from collision of replication forks 
with cleaved complexes containing gyrase or topoisomerase 
IV, a small number of non-lethal (repairable) breaks pro-
bably arise. One line of evidence emerges from the signature 
response to quinolone treatment, the induction of the SOS 
regulon [74-77]. Quinolone-mediated induction of the SOS 
response requires the action of RecBCD, which in turn 
requires a free DNA end to load onto DNA. Consequently, it 
is likely that some double-strand breaks are generated by 
collision of replication forks with cleaved complexes. 
Indeed, in a plasmid model system where cleaved complex 
formation blocked replication, double-strand breaks were 
observed [78, 79].  
  It has been suggested that the double-strand DNA breaks 
arising after replication fork stalling are generated by a 
recombination nuclease [78, 79]. Interestingly, a significant 
portion of the double-strand breaks associated in vivo with 
cleaved complexes and blockage of replication fork 
progression are reversible [79]. When replication forks are 
stalled  in vivo, they trigger ‘replication restart’ processes 
catalyzed by recombination proteins [80-83]. It is presently 
unclear which recombination proteins are involved in 
quinolone-induced generation of double-strand breaks. One 
candidate is the RuvABC complex. Since RuvAB can 
reverse a topoisomerase IV-quinolone-DNA ternary complex 
in vitro [84], it is possible that RuvAB may reverse and 
dissociate the cleaved complex at a stalled replication fork 
before RuvC cleaves DNA to generate a double-strand break 
[79]. While we consider it important to distinguish the few 
DNA breaks associated with replication fork arrest from the 
extensive chromosome fragmentation associated with cell 
death (discussed below), it is conceivable that some repair 
proteins are involved in both.  
LETHAL ACTION OF QUINOLONES  
Quinolone Generations and Pathways to Cell Death 
  The quinolones kill E. coli by two pathways. One is bloc-
ked by inhibitors of protein synthesis, such as chloram-
phenicol, and by anaerobic conditions. The second pathway 
is active even in the presence of chloramphenicol or the 
absence of oxygen. Four structural quinolone generations are 
distinguished by the effects of chloramphenicol and 
anaerobiosis on quinolone lethality [63]. First-generation 
compounds, such as nalidixic and oxolinic acids, are not 
lethal in the presence of chloramphenicol or during 
anaerobic growth; the second-generation agent norfloxacin 
fails to kill E. coli in the presence of chloramphenicol, but at 
high concentrations it kills cells growing anaerobically 
(norfloxacin also kills E. coli suspended in saline, while 
nalidixic acid does not). Ciprofloxacin, a third-generation 
compound, kills under both conditions but requires higher 
concentrations during anaerobiosis; the lethal activity of 
fourth generation C-8-methoxy derivatives, such as   
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PD161144, is affected little by chloramphenicol or anaerobic 
growth. These data fit with the idea that some compounds 
function more through one pathway than the other. The 
choice of pathway depends on quinolone concentration, 
since even the fourth-generation compounds are sensitive to 
chloramphenicol if quinolone concentrations are low 
enough. 
  The two lethal pathways are also observed in mycobac-
teria. For example, with M. tuberculosis gatifloxacin and 
moxifloxacin, two C-8-methoxy compounds, are indistin-
guishable when lethal activity is measured with growing 
cultures. However, when chloramphenicol is added, moxi-
floxacin is strikingly more active [85]. Moxifloxacin is also 
more active when growth of M. bovis BCG is arrested by 
treatment with nitric oxide [86]. Since the two fluoro-
quinolones differ only in their C-7 ring systems, we can 
begin to attribute death of non-growing cells to the C-7 
substituent. 
Chromosome Fragmentation 
 Since quinolone-enzyme-DNA complexes contain 
broken DNA and since chromosome fragmentation is likely 
to kill cells [87], we postulated that cell death arises from the 
release of DNA breaks from protein-mediated constraint 
existing in the cleaved complexes. The first evidence for this 
idea came from supercoiling studies with E. coli nucleoids, 
as pointed out in the introduction [61]. Treatment with lethal 
concentrations of oxolinic acid allowed relaxation of DNA 
supercoils, an event that failed to occur when cells were 
pretreated with chloramphenicol. In these experiments high 
concentrations of ethidium bromide, a DNA-intercalating 
agent, failed to introduce positive supercoils, indicating that 
the DNA relaxation arose from DNA breakage. Cipro-
floxacin, a compound that kills cells in the presence of 
chloramphenicol, relaxed supercoils whether or not protein 
synthesis was blocked. This correlation between cell death 
and chromosome fragmentation was subsequently streng-
thened by sedimentation and viscometric measurements [88]. 
  Insight into the chloramphenicol-insensitive lethal 
pathway came initially from work by Ikeda. His laboratory 
found a form of quinolone-stimulated illegitimate recombi-
nation that was attributed to gyrase subunit dissociation-
reassociation [89, 90]. Quinolone-mediated gyrase subunit 
dissociation could explain lethality that is unaffected by 
chloramphenicol: in the cleaved complexes the quinolones 
might pry gyrase subunits apart and fragment chromosomes. 
This idea is supported by the ability of gatifloxacin to 
fragment isolated chromosomes in the presence of purified 
gyrase. Moreover, a GyrA A67S variant is killed by nalidixic 
acid in the presence of chloramphenicol [88], an event that 
does not occur with wild-type cells. In this variant an Ala 
residue expected to lie on the GyrA-GyrA dimer interface is 
substituted by Ser, a change that could weaken hydrophobic 
interactions and promote subunit dissociation. So far, no 
structural model of the cleaved complex explains lethal 
action. 
  The basis of chromosome fragmentation that requires 
ongoing protein synthesis is even less clearly defined. The 
three most obvious mechanisms for releasing DNA breaks 
from protein-mediated constraint are 1) protease digestion of 
gyrase, 2) nuclease-mediated cleavage on either side of the 
cleaved complex, and 3) protein denaturation. Once this 
fragmentation occurs, death arises from ROS, as described 
below. 
Amplification of Lethal Action by Reactive Oxygen 
Species 
  Collins and co-workers recently discovered that hydroxyl 
radical concentrations are elevated in E. coli following treat-
ment with several lethal antimicrobials, including norflo-
xacin [91, 92]. We subsequently found that when both sodA 
and sodB were deficient, norfloxacin lethality was reduced. 
These data are consistent with superoxide dismutase 
normally promoting quinolone lethality, perhaps by stimu-
lating formation of peroxide [93]. A deficiency in 
catalase/peroxidase (katG) also elevated the lethal activity of 
norfloxacin, a result that was expected because a buildup of 
peroxide should lead to accumulation of highly toxic 
hydroxyl radical [93].  
 Collins  et al. also reported that bacteriotstatic concen-
trations of thiourea or 2,2’-bipyridyl, agents expected to 
reduce the level of hydroxyl radical, inhibit norfloxacin 
lethality [91]. That led to the conclusion that hydroxyl 
radical contributed to quinolone lethality [91]. Since 
inhibiting growth of E. coli is known to block norfloxacin 
lethality, thiourea and 2,2’-bipyridyl treatment was 
reinvestigated at subinhibitory concentrations. Even then the 
two agents interfered with norfloxacin-mediated killing [93]. 
Thus, ROS are very likely to play a role in quinolone-
mediated lethality. 
  Since norfloxacin displays a complex behavior with 
respect to lethal action [63], we reinvestigated the role of 
ROS using oxolinic acid, which kills only by the 
chloramphenicol-sensitive pathway. Like chloramphenicol, 
thiourea plus 2,2’-bipyridyl almost completely blocks the 
lethal action of oxolinic acid [94]. But only chloramphenicol 
blocks chromosome fragmentation (X. Wang and X.Z., 
unpublished observation). Thus, the chromosome fragmen-
tation step occurs before the ROS step. Apparently 
chromosome fragmentation caused by oxolinic acid can be 
repaired, which explains the ability of inhibitors of ROS to 
almost completely block cell death (in the next section we 
discuss a possible involvement of the Lon protease in repair). 
As expected, a surge of hydroxyl radical accumulation 
follows oxolinic acid treatment, and that surge is blocked by 
chloramphenicol (X. Wang and X. Z., unpublished results).  
  Lethal action of PD161144, a C-8-methoxy fluoro-
quinolone that kills E. coli by the subunit dissociation 
pathway, is affected little by treatment with chloramphenicol 
or thiourea plus 2,2’-bipyridyl or all three agents together 
(X. Wang and X.Z., unpublished observations). These data 
further distinguish the two lethal pathways, and they suggest 
that lethality from subunit dissociation is independent of 
ROS generation. 
LON PROTEIN AND REPAIR OF QUINOLONE-
MEDIATED LESIONS  
  Lon protease degrades abnormal proteins and proteins 
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Lon influences a variety of physiological phenomena, 
including cell differentiation, sporulation, pathogenicity, and 
survival during starvation and anaerobic conditions. The Lon 
protein has ATPase activity, and part of the ATPase domain 
binds DNA. As a result, early studies identified Lon as a 
double-strand DNA binding protein [96]. Large DNA 
molecules stimulate both the ATPase and the protease 
activities of Lon, which led to speculation that Lon might 
bind chromosomal DNA adjacent to regulatory proteins 
where it could control their turnover [97]. However, several 
in vitro studies show that the interaction of bacterial Lon 
with large DNA molecules lacks nucleotide sequence-
specificity [98]. Nevertheless, Lon remains a candidate for 
removal of proteins, such as topoisomerases, trapped on 
bacterial chromosomes.  
  We first noticed a role for Lon protease in chromosome 
maintenance when examining paradoxical survival of 
bacteria at very high concentrations of quinolone [99]. A 
deficiency of Lon protease eliminates paradoxical survival 
[100]. Plasmid-borne protease activity of Lon restores the 
paradoxical behavior of quinolones, while ATPase activity 
does not. These observations confirm that Lon is necessary 
for paradoxical survival and indicate that the protease 
activity is indispensable. 
  To determine whether Lon affects chromosomal breaks 
in cleaved complexes, an empirical viscometric assay was 
applied to lysates of cells treated with various concentrations 
of nalidixic acid. When SDS was added to cell lysates to 
unfold chromosomes and release broken DNA from cleaved 
complexes, viscosity of lysates paralleled the lethal effect of 
nalidixic acid, initially dropping as nalidixic acid killed cells 
and then rising as high drug concentrations protected from 
death. In the Lon-deficient mutant, cell lysate viscosity was 
low when cells were treated with the high drug concen-
trations that had been rendered lethal by the lon mutation. 
Thus, cleaved complexes paralleled bactericidal effects, 
including those influenced by Lon.  
  Lon may also recognize and help repair other forms of 
cleaved complexes. One involves the derivative of ciproflo-
xacin containing an N-bromoacetyl C-7 piperazinyl group 
(Cip-Br). We expected the bromo substituent to form cross-
links with a nearby cysteine, and bacterial strains having a 
Gly-81 Cys substitution in GyrA were exceptionally suscep-
tible to Cip-Br. Moreover, inhibition of DNA synthesis by 
the quinolone was not reversed by washing cells with drug-
free medium (M.M. and A.M. unpublished observations). 
However, lack of reversal by Cip-Br was seen only in a Lon-
deficient strain, as if preferential recognition and removal of 
Cip-Br-Cys complexes by Lon obscured the irreversibility of 
putative drug-gyrase crosslinking.  
  A third example of Lon-mediated protection from 
quinolone was observed following treatment of E. coli cells 
with chloramphenicol, a bacteriostatic agent. With wild-type 
cells, chloramphenicol blocks further killing by oxolinic 
acid, even when added an hour after the quinolone. 
However, in Lon-deficient strains, chloramphenicol fails to 
rapidly halt quinolone-mediated cell death. If chloram-
phenicol is added before quinolone, the absence of Lon has 
no effect. These data are consistent with Lon being involved 
in the repair of lethal lesions formed by quinolones, lesions 
whose formation is blocked by chloramphenicol. Whether 
Lon-mediated repair involves direct removal of the 
complexes or an indirect effect due to rapidly removing an 
unidentified lethal factor involved in fragmentation of DNA 
is not known. 
  Each example of Lon action on cleaved complexes 
involves a situation in which the complex may have an 
unusual structure (extra drug molecules bound at the high 
quinolone concentrations that allow paradoxical survival, 
cross-linked drug-gyrase complexes formed with Cip-Br, 
and lethal, rather than reversible complexes after prolonged 
quinolone treatment). A Lon deficiency has no observable 
effect on nalidixic acid-mediated killing in an otherwise 
wild-type strain at low to moderate concentrations [100]. 
Under these conditions, Lon-mediated repair may be unable 
to compete with ROS-mediated killing. 
  We next turn to quinolone resistance. For many years, the 
prevalence of resistance was low for most pathogens, and the 
absence of plasmid-borne resistance was touted as one of the 
virtues of the fluoroquinolones. Heavy medical and 
agricultural use has negated both statements.  
MUTANT SELECTION WINDOW 
Stepwise Selection of Resistance Mutants 
  As with many antimicrobials, resistance to fluoroquino-
lones is conferred by genetic variations that reduce 
intracellular drug concentration (e.g. activation of efflux 
pumps) and/or reduction of the affinity of the compound for 
its target. With some pathogens, a single mutation, either 
chromosomal or plasmid-borne, is insufficient for clinical 
resistance. In such cases, it is often the accumulation of 
multiple changes that lowers susceptibility enough to 
achieve resistance. If the initial drug concentration is low, 
non-target alleles will be selected, as seen with mycobacteria 
and S. pneumoniae [19, 101, 102]. If the initial concentration 
is moderately high, target mutations are selected [19, 103, 
104, 102]. After the population acquires one mutation, a 
second emerges [105]. The order in which target and 
nontarget alleles arise probably depends on the incremental 
increase in quinolone concentration. Repeated cycles of 
fluoroquinolone challenge, punctuated by periodic outgrowth 
of pathogen populations, are expected to cause stepwise 
accumulation of mutations and therefore a wide variety of 
resistant mutants [14, 106].  
  The gradual accumulation of resistance alleles causes 
surveillance studies to underestimate the emergence of 
resistance, since strains can contain resistance mutations and 
still be considered clinically susceptible by MIC breakpoint 
criteria. Those mutations increase the propensity for 
attaining additional resistance determinants by raising the 
upper limit of the selection window (discussed below). 
Eventually strains accumulate enough mutations for MIC to 
exceed the resistance breakpoint. Dissemination of these 
resistant mutants can then cause a rapid increase in the 
prevalence of resistance, as has been observed with S. aureus 
[107, 108]. Consequently, resistance can appear to arise 
suddenly even though the early stages are intrinsically 
gradual. To see the early stages it is necessary to perform a 
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culture are applied to antibiotic-containing agar plates and 
resistant colonies are counted [109]. The colonies that arise 
reflect the mutant subpopulations present in the culture.  
Mutant Selection Window Hypothesis 
  In the late 1990s we noticed that the recovery of myco-
bacterial mutants from agar plates displays a characteristic 
response to fluoroquinolone concentration [102, 110]. At 
low concentrations, the drug has no effect on colony 
formation until MIC is approached; then colony recovery 
drops sharply as susceptible growth is blocked. As drug 
concentrations increase, a broad plateau is observed, since a 
variety of resistant mutant subpopulations can grow and 
form colonies at those levels of drug exposure. Eventually a 
high concentration is reached at which colony recovery 
drops sharply a second time. The second drop correlates with 
the MIC of the least susceptible first (single)-step mutant 
subpopulation. This value is designated as the mutant 
prevention concentration (MPC) because it severely limits 
the recovery of resistant mutants. At concentrations above 
MPC, bacterial growth requires the acquisition of two or 
more concurrent resistance mutations, which is a rare event. 
At low drug concentrations (slightly below MIC), selection 
pressure is greatly diminished because resistant mutants have 
no growth advantage over susceptible cells. Thus, the 
selective amplification of resistant mutants occurs in a drug 
concentration range that is above MIC but below MPC. This 
drug concentration range is called the mutant selection 
window.  
Experimental Support for the Selection Window 
Hypothesis 
  Since the mutant selection window was derived from 
static measurements, either with agar plates [110] or with 
large volumes of liquid medium [111], it was important to 
determine whether the window also exists when drug 
concentrations fluctuate. Measurements with in vitro 
dynamic models show that the window can be observed with 
fluctuating antimicrobial concentrations for fluoroquino-
lones, vancomycin, and daptomycin [112-121]. It is also 
readily seen in rabbits infected with S. aureus and treated 
with levofloxacin [122]. With both in vitro and in vivo 
experiments, static data fit well with dynamic measurements. 
  The selection window hypothesis differs qualitatively 
from the conventional idea in which the danger zone for 
selection of resistant mutants lies below MIC [123] rather 
than between the MIC and MPC [124]. The two ideas make 
different predictions about the emergence of resistance. 
According to the conventional view, eradication of the 
susceptible population will suppress acquisition of resistance 
(“Dead bugs don’t mutate” [125]). In contrast, the selection 
window hypothesis maintains that resistance can emerge 
even when the susceptible population is eliminated, because 
resistant mutants may exist in a bacterial population prior to 
the start of antibiotic treatment. Treatment then allows 
mutant enrichment and amplification. In vitro and animal 
studies described above support the window hypothesis, as 
does a small clinical trial [126]. In the clinical study, newly 
hospitalized tuberculosis patients were screened for nasal 
colonization by S. aureus and then treated for tuberculosis 
using a protocol in which rifampicin was the only agent 
active with S. aureus. After several weeks, patients were 
again sampled for S. aureus nasal colonization. In 92% of 
the cases, S. aureus colonization was eliminated, which 
showed that the treatment was effective. The other 8% of the 
colonizing isolates became rifampicin resistant. DNA 
analyses indicated that the resistant isolates evolved from the 
original, susceptible ones rather than from re-infection with 
different strain types. Collectively, these are the results 
predicted by the window hypothesis for a situation in which 
drug concentration is inside the selection window during 
treatment (MPC for rifampicin resistance is very high [20], 
which placed therapeutic concentrations inside the selection 
window). 
Lethal Action and Resistant Mutant Selection 
  One of the predictions of the selection window hypo-
thesis is that the emergence of resistance can be restricted by 
keeping drug concentrations above the selection window. 
This strategy is based on blocking mutant growth. Lethal 
action is an added effect that directly reduces susceptible 
pathogen numbers. That should help shorten treatment times, 
which in turn should reduce costs, toxic side effects, and the 
chance that new resistance will develop. Removal of the 
major population of susceptible cells should also increase the 
probability that host defense systems will eliminate resistant 
mutants.  
  Lethal action has additional importance for fluoro-
quinolones having gyrase as their primary target because 
gyrase-mediated resistance is genetically recessive. A 
recessive resistance mutation is not phenotypically expressed 
until the resistant, mutant protein has replaced most of the 
sensitive, wild-type copies (E. coli contains more than a 
thousand gyrase molecules per cell and hundreds of cleaved 
complexes form on chromosomes [8, 70, 127]). Until that 
time, the mutants will still be killed by the quinolone. 
Consequently, compounds that are more lethal will be better 
at restricting the selection of newly formed resistant mutants. 
When topoisomerase IV is the main target, resistance is 
codominant [60]; consequently, resistance would be 
expressed soon after the mutation occurred. In this situation 
lethal action would not have as great an effect as when 
resistance is recessive. Recessive-dominant considerations 
may partly explain why the frequency for obtaining target 
mutants of S. pneumoniae is 1,000 times higher for 
fluoroquinolones whose primary target is topoisomerase IV 
rather than gyrase [19, 128].  
Pharmacodynamics and the Selection Window 
  Some of the complexities of lethal action on the selection 
window can be bypassed by empirical PK/PD conside-
rations, since they take into account both bacteriostatic and 
bactericidal activity. For antimicrobial pharmacodynamics, 
the efficacy of a compound is commonly related to two 
parameters, its potency against the bulk population of a 
particular pathogen, usually measured as MIC of the patho-
gen culture, and the concentration achieved at the site of 
infection. For the so-called concentration-dependent killers, 
such as fluoroquinolones, the two parameters are conven-
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concentration curve in a 24-hr period (AUC24) by MIC. This 
pharmacodynamic index (AUC24/MIC) correlates empiri-
cally with favorable patient and microbiological outcome 
[129, 130]. To extend this idea to restricting resistant 
subpopulation enrichment, MIC is replaced with MPC (the 
MIC of the least susceptible mutant subpopulation). Thus, a 
value of AUC24/MPC can be determined experimentally to 
define the upper boundary of the mutant selection window; 
that value takes into account lethal activity of fluoro-
quinolones with resistant mutants [131, 132] and better 
defines  in vivo window boundaries [122]. Consequently, 
treatment with lethal agents should require maintenance of 
fluoroquinolone concentrations above MPC long enough for 
killing to occur, but not throughout therapy, as would be the 
case for bacteriostatic agents. Experimentally, restricted 
amplification of resistant mutant subpopulations requires 
fluoroquinolone concentrations to be above MPC for only 
20% of the dosing interval when S. aureus is treated with 
levofloxacin [122]. 
  A general population-based approach has been developed 
to relate dose and patient outcome through measurements of 
AUC24/MIC [123, 133, 134]. The idea can also be used to 
evaluate particular doses for their ability to restrict the 
emergence of resistance [132]. Briefly, an animal model of 
infection is used to determine a target value of AUC24/MPC 
at which no resistance emerges. Then the ability of a given 
dose to attain the targeted AUC24/MPC with a human 
population is estimated by 1) determining AUC24 for the 
given dose using a patient population, 2) determining 
pathogen MPC for the compound using isolates from the 
patient population to be treated, and 3) mathematically 
combining the population AUC24 and pathogen population 
MPC. Due to the pharmacokinetic diversity of patient 
populations and susceptibility diversity of bacterial isolates, 
the output is the fraction of the patient population that will 
reach the pharmacodynamic target using a particular dose. 
Widespread use of this method requires additional measure-
ments of pathogen population MPC [135-137] since MIC 
cannot be reliably used to predict MPC [138, 139]. 
Practical Importance of the Window Hypothesis 
  A major feature of the hypothesis is that it reveals one 
reason why emergence of resistance is occurring: clinical 
treatments place drug concentrations inside the window for 
long periods of time. That facilitates mutant enrichment 
unless host defenses eliminate or block proliferation of 
mutant subpopulations. It also provides a general approach 
for slowing the emergence of resistance: keep drug concen-
trations above the window or use combination therapy. 
Applying this strategy is difficult because no existing 
antimicrobial has been developed using selection window 
principles. Moreover, restricting resistance generally requires 
higher doses than needed to cure most patients; 
consequently, toxic side effects become an issue. However, 
human pharmacokinetics for approved doses are known, and 
MPC has been measured for many drug-pathogen combi-
nations. Consequently, compounds can be compared for their 
ability to restrict the emergence of resistance.  
 
QUINOLONE-INDUCED QUINOLONE RESISTANCE 
  The mutant selection window addresses selective 
amplification and enrichment of resistant mutants, but it does 
not consider the important property of mutant induction: the 
quinolones induce the mutagenic SOS response. To examine 
the effect of quinolone structure on the recovery of resistant 
mutants during drug exposure, we applied E. coli to agar 
plates containing various compounds, and at daily intervals 
we counted the cumulative number of colonies (this assay 
had been used previously to assess the effect of various 
mutations on induction of resistance [140, 141]). With E. 
coli, colonies seen after one day of incubation estimate a 
baseline of mutants pre-existing in the test culture. The 
number then increases over the next week. The rate of 
mutant accumulation probably depends on a complex set of 
factors that includes the rate at which wild-type cells are 
killed and blockage of mutant growth (M.M., unpublished 
observations). A methoxy group at position C-8 is parti-
cularly restrictive, and a quinazoline-2,4-dione is much more 
effective than its cognate fluoroquinolone. Thus, a simple 
agar-plate assay is available to compare compounds for the 
ability to restrict the mutagenic effects of quinolones and 
related antimicrobials.  
NEW QUINOLONE-LIKE MOLECULES HAVING 
ANTI-MUTANT ACTIVITY  
  Antimicrobial development conventionally involves 
identifying new derivatives that are active against resistant 
mutants already enriched by earlier derivatives of the class. 
This approach keeps the clinician one step ahead of the 
pathogen. Experience tells us, however, that many pathogens 
can easily make one mutational step. New compounds are 
likely to have a longer life span if they require pathogens to 
acquire two or more concurrent resistance mutations for 
growth in the presence of the antibiotic. If the mutant 
selection window is closed, i.e. if MIC = MPC, two 
mutational steps will be required for growth. Thus, a goal of 
quinolone development is to close the selection window. 
That can be accomplished in two general ways. One requires 
a compound to have very good activity against resistant 
mutant subpopulations; the other involves a single agent 
having two independent targets with similar susceptibility or 
two agents having independent targets. Examples using the 
two general approaches are described below. 
Closing the Selection Window with a Single Agent 
Having a Single Target 
  MPC is the MIC of the least susceptible, first-step 
resistant mutant subpopulation. MPC may be difficult to 
measure with some compounds and some bacteria because 
large numbers of organisms must be tested (on the order of 
10
10). As an initial screen, compounds can be tested for anti-
mutant activity. This activity is defined as the MIC of a 
known resistant mutant divided by the MIC of an isogenic 
wild-type (susceptible) strain. When a battery of resistant 
mutants is examined, compounds can be compared for their 
ability to suppress the growth of mutants: compounds are 
sought that have MICmutant/MICwt  1. Then it is necessary to  
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measure MPC, since the battery of existing mutants may not 
have accurately represented the least susceptible resistant 
mutant subpopulation. For example, the novel compound 
being tested could have switched targets from gyrase to 
some other enzyme. Such a compound might be effective 
against existing gyrase mutants, but it would not necessarily 
have a narrow selection window, which could allow 
resistance to readily emerge.  
 Ellsworth  et al. showed that the conversion from a 
quinolone core structure to a 3-amino-quinazoline-2,4-dione 
structure afforded gyrase inhibitors that are active against 
known quinolone-resistant mutants of E. coli, S. aureus, and 
S. pneumoniae [142-146]. Structurally similar pyrido[1,2-
c]pyrimidine-1,3-diones appear to possess comparable 
activities [147], and we recently described an optimized 
synthesis of the 1,3-dione core ring system [148]. As a test 
of the anti-mutant approach, we prepared and evaluated a 
series of 3-amino-8-methoxy-quinazoline-2,4-diones (Fig. 3) 
against quinolone-resistant E. coli mutants. By varying dione 
structure at the N-3 and C-7 positions, we were able to 
identify derivatives that brought the ratio of mutant to wild-
type MIC close to unity [149], thus showing that optimized 
quinazoline-2,4-diones drastically reduce the protective 
effects of quinolone-resistant mutations in gyrA and gyrB of 
E. coli. Structural changes that lowered the ratio of mutant to 
wild-type MIC also lowered the absolute MIC. Moreover, 
the most bacteriostatic 2,4-dione exhibited rapid lethality 
similar to the cognate fluoroquinolone when normalized to 
MIC to correct for drug uptake/efflux [149]. When 
population analysis was performed with E. coli to examine 
the ability of the most active 2,4-dione to restrict the 
selection of resistant mutants, mutants were selected over a 
much narrower concentration range for the most active 8-
methoxy-2,4-dione tested than for the cognate fluoro-
quinolone or for ciprofloxacin [149].  
 
 
 
 
 
 
Fig. (3). Representative 3-amino-8-methoxy-quinazoline-2,4-dione 
and 5-methoxy-pyrido [1,2-c]pyrimidine-1,3-dione structures. 
Compounds Active Against More than One Target 
  Some newer fluoroquinolones, des-fluoroquinolones, and 
other uniquely substituted derivatives target DNA gyrase and 
topoisomerase IV of certain organisms with near equipotent 
activity [150-154]. Analogs of other quinolone-like struc-
tural scaffolds, such as some heteroaryl isothiazolones (Fig. 
4), also show equipotent targeting of DNA gyrase and 
topoisomerase IV [155]. Consequently, a strain with a first-
step mutation in one topoisomerase, DNA gyrase or 
topoisomerase IV, would still be inhibited by action at the 
other target. When the susceptibility of the two targets is 
equal, no selection window exists; for growth, a mutant must 
concurrently acquire mutations in both genes encoding the 
targets. The benefit of dual-targeting quinolones to slow the 
selection of quinolone-resistant mutants is negated when 
these agents are employed against M. tuberculosis and other 
organisms that lack topoisomerase IV. 
  Another approach to creating dual targeting compounds 
is to link members of different antibacterial classes. Indeed, 
conjugating two antibiotics to give multi-targeting agents has 
been studied by many groups with many antibacterial agents 
[156, 157]. With quinolones, this approach is exemplified by 
covalently linked rifamycin-fluoroquinolone conjugates 
[158, 159] and oxazolidinone-quinolone conjugates [160]. 
Low mutation frequency and good activity against quino-
lone-resistant gyrase mutants is observed because the 
conjugates are derived from antibacterial agents having 
different molecular targets. The same approach can be used 
with separate agents in combination therapies. Variations in 
potency of the individual components of conjugates and 
pharmacokinetic differences still allow emergence of 
resistance, albeit at a slower rate. 
PLASMID-MEDIATED QUINOLONE RESISTANCE 
  Resistance carried by plasmids poses two threats to 
quinolone efficacy. First, plasmids can transmit resistance to 
multiple antimicrobials, thereby allowing quinolone resis-
tance to be selected by use of other antibiotic classes and 
vice versa. Second, plasmids can introduce resistance 
determinants into a bacterial population at a much higher 
frequency than occurs through spontaneous mutation [161-
163]. As a result, resistance is expected to emerge more 
rapidly from plasmid-borne resistance genes than from 
spontaneous mutations. The practical implication is that 
infections caused by pathogens containing drug-resistant 
plasmids need to be treated with elevated drug concentration 
even though the bulk population may be considered 
susceptible.  
  Three forms of plasmid-mediated quinolone resistance 
have been identified. The first and best studied involves Qnr 
[164], a protein that interferes with quinolone binding to 
gyrase and topoisomerase IV. The second type expresses the 
quinolone-acetylating Aac (6')-Ib-cr enzyme that inactivates 
compounds such as ciprofloxacin [165, 166]. The third 
involves an efflux pump encoded by qepA [167]. Of the 
three, Qnr appears to have the most activity, increasing MIC 
up to 250 fold (QepA increases MIC by 10 fold [168] and 
Aac (6')-Ib-cr by 4 fold [165]). Below we focus on Qnr. 
  Qnr was discovered in a strain of Klebsiella pneumoniae 
exhibiting resistance to fluoroquinolones and 13 other agents 
[164]. The discovery of related proteins (QnrB [169] and 
QnrS [170]) subsequently caused the original protein to be 
renamed QnrA. QnrA is a 218-amino-acid protein that 
belongs to a large protein family characterized by pentapep-
tide repeats (the pentapeptide protein family includes 
roughly 500 members that display a wide variety of 
properties [171, 172]). Insight into how the gyrase-protecting 
subclass might act came from structural analysis of MfpA 
[173], a Qnr homologue found in mycobacteria [174]. When 
MfpA was expressed in E. coli, purified, and crystallized, its 
three-dimensional structure revealed that the protein dimer 
has size, shape, and electrostatic similarity to B-form DNA 
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  The Qnr proteins lower quinolone binding to DNA 
complexes formed with gyrase or topoisomerase IV [175]. 
Binding of Qnr to the two enzymes appears to be specific 
rather than a general protein-binding property, and it does 
not require quinolone, DNA, or ATP [176]. Qnr also 
reverses quinolone-mediated inhibition of the supercoiling 
activity of gyrase [176]. Even a 1,000-fold excess of 
ciprofloxacin fails to overcome the Qnr-gyrase interaction; 
consequently, Qnr is likely to act by altering the DNA-
binding properties of gyrase rather than by competitive 
binding to a quinolone interaction site [176]. Since quino-
lone resistance arises in a stepwise fashion, reduced 
susceptibility due to the presence of qnr is expected to be an 
important factor in the emergence of resistance, either by 
adding to the effect of an existing resistance allele to render a 
strain clinically resistant or by serving as an early step in the 
pathway to resistance. As expected, increased MPC has been 
reported with Qnr-containing bacteria [13]. 
  Often plasmids having a QnrA determinant also carry 
genes that confer resistance to other anti-bacterials, such as 
aminoglycosides,  -lactams, chloramphenicol, and 
sulfonamides [177]. The presence of multiple antibiotic 
resistance genes on the same plasmid explains the frequent 
multidrug-resistant phenotype of Qnr-positive enterobac-
terial isolates. The fluoroquinolone-resistance plasmids are 
conjugative and carry both integrons and transposons [177]. 
They also have a broad host range: the plasmids have been 
obtained from a variety of enterobacteria including 
Citrobacter freundii, C. koseri, Enterobacter aerogenes, E. 
amnigenus, E. cloacae, E. sakazakii, E. coli, Klebsiella 
oxytoca, K. pneumoniae, Providencia stuartii, Salmonella 
enterica, Serratia marcescens, Shigella dysen-teriae, and S. 
flexneri [178-181]. Moreover, Qnr-expressing plasmids are 
widely distributed with respect to geography [177]. For 
example, they have been isolated in Bangladesh [182], China 
[183-185], France [186], Germany [187], Korea [180], Japan 
[170], Taiwan [188], Thailand [189], Turkey [190], United 
Kingdom [191], and the United States [181, 192]. Thus, we 
expect qnr to cause serious resistance problems. 
  The genes responsible for the other two types of plasmid-
borne resistance have not been studied as extensively as qnr. 
The quinolone-acetylating Aac (6')-Ib-cr enzyme inactivates 
compounds such as ciprofloxacin by placing an acetyl 
substituent on the unsubstituted nitrogen of the C-7 
piperazinyl ring [165]. The enzyme also lowers susceptibility 
to norfloxacin, which has the same C-7 ring as ciprofloxacin. 
However, it has no effect on quinolones, such as enroflo-
xacin, pefloxacin, levofloxacin, and gemifloxacin, that lack 
an unsubstituted piperazinyl nitrogen [193]. So far, bacterial 
isolates carrying the aac (6')-lb-cr gene have been recovered 
from China [165, 185], France [194], the United States [15], 
and Uruguay [195] in a variety of Enterobacteriaceae such as 
C. freundii,  E. cloacae,  E. coli, and K. pneumoniae [195, 
185]. The other plasmid-borne resistance factor, the QepA 
efflux pump, was first found in 2006 in a clinical isolate of 
E. coli from Japan [167]. MIC for hydrophilic fluoroquino-
lones, such as norfloxacin and ciprofloxacin, increases by 10 
fold compared with plasmid-free counterparts [168]. So far, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Representative newer quinolone-class antibacterial agents found to be equipotent or near equipotent inhibitors of both DNA gyrase 
and topoisomerase IV. It is notable that each structure differs from early generation fluoroquinolones (e.g. ciprofloxacin and norfloxacin) by 
having a position-8 group other than simple aryl hydrogen. Quinolones: action and resistance updated  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11     993 
the prevalence of QepA-mediated resistance in humans is 
low (0.3% among E. coli isolates collected from 140 
Japanese hospitals between 2002 and 2006 [167]; 0.8% of 
ESBL-producing enterobacterial isolates collected in France 
during 2007 [196]).  
CONCLUDING REMARKS 
  The quinolones continue to be an important class of 
antimicrobial agent. The reaction mechanism of the target 
enzymes is understood in considerable detail, and it is clear 
that formation of drug-enzyme-DNA complexes is the 
central event in quinolone action. However, our knowledge 
of these complexes is far from complete. For example, a 
crystal structure of the complex has been reported [33], but 
an additional structure may be required to explain what is 
likely to be multistep binding [197]. Release of DNA breaks 
from cleaved complexes and the resulting chromosome 
fragmentation continues to explain lethal action, although 
with the older quinolone derivatives it is clear that death 
ultimately arises from the accumulation of hydroxyl radicals. 
How the DNA breaks are released from protein-mediated 
constraint and how they promote a cascade of reactive 
oxygen species is unknown. The newer fluoroquinolones 
also cause an ROS surge, but chromosome fragmentation 
appears to kill faster than ROS. 
  Bacterial resistance to the quinolones is a growing 
problem [198-200]. Many aspects are now predictable within 
the framework of the mutant selection window hypothesis: 
continued use of dosing regimens that place drug 
concentrations inside the selection window for long periods 
of time will surely erode the usefulness of the compounds. 
Whether keeping concentrations above the window suffi-
ciently restricts the emergence of resistance remains to be 
seen, especially since plasmid-borne resistance is becoming 
widespread. Assays are now available to screen new 
compounds for the ability to restrict mutant amplification, 
and new derivatives are emerging. Thus, the future remains 
bright for the quinolone class if the research developments 
are exploited judiciously. 
ACKNOWLEDGEMENTS 
  We thank the following for critical comments on the 
manuscript: Marila Gennaro, Shajo Kunneth, Richard Pine, 
and Lynn Zechiedrich. The work was supported by NIH 
grants AI063431, AI35357, AI073491, AI068014, and 
GM30717-21. 
REFERENCES 
[1]  Gellert, M.; Mizuuchi, K.; O'Dea, M.H.; Itoh, T.; Tomizawa, J.-L. 
Nalidixic acid resistance: a second genetic character involved in 
DNA gyrase activity. Proc. Natl. Acad. Sci. USA 1977, 74, 4772-
4776. 
[2]  Kato, J.-I.; Nishimura, Y.; Imamura, R.; Niki, H.; Hiraga, S.; 
Suzuki, H. New topoisomerase essential for chromosome 
segregation in E. coli. Cell 1990, 63, 393-404. 
[3]  Hiasa, H.; DiGate, R.; Marians, K. Decatenating activity of 
Escherichia coli DNA gyrase and topoisomerases I and III during 
oriC and pBR322 DNA replication in vitro. J. Biol. Chem. 1994, 
269, 2093-2099. 
[4]  Kreuzer, K.N.; Cozzarelli, N.R. Formation and resolution of DNA 
catenanes by DNA gyrase. Cell 1980, 20, 245-254. 
[5]  Mizuuchi, K.; Fisher, L.M.; O'Dea, M.; Gellert, M. DNA gyrase 
action involves the introduction of transient double-strand breaks 
into DNA. Proc. Natl. Acad. Sci. USA 1980, 77, 1847-1851. 
[6]  Peng, H.; Marians, K. Decatenation activity of topoisomerase IV 
during  oriC and pBR322 DNA replication in vitro.  Proc. Nat. 
Acad. Sci. USA 1993, 90, 8571-8575. 
[7]  Sugino, A.; Peebles, C.; Kruezer, K.; Cozzarelli, N. Mechanism of 
action of nalidixic acid: purification of Escherichia coli nalA gene 
product and its relationship to DNA gyrase and a novel nicking-
closing enzyme. Proc. Natl. Acad. Sci. USA 1977, 74, 4767-4771. 
[8]  Snyder, M.; Drlica, K. DNA gyrase on the bacterial chromosome: 
DNA cleavage induced by oxolinic acid. J. Mol. Biol. 1979, 131, 
287-302. 
[9]  Hiasa, H.; Yousef, D.; Marians, K. DNA strand cleavage is 
required for replication fork arrest by a frozen topoisomerase-
quinolone-DNA ternary complex. J. Biol. Chem. 1996, 271, 26424-
26429. 
[10]  Wentzell, L.; Maxwell, A. The complex of DNA gyrase and 
quinolone drugs on DNA forms a barrier to the T7 DNA 
polymerase replication complex. J. Mol. Biol. 2000, 304, 779-791. 
[11]  Willmott, C.J.R.; Critchlow, S.E.; Eperon, I.C.; Maxwell, A. The 
complex of DNA gyrase and quinolone drugs with DNA forms a 
barrier to transcription by RNA polymerase.  J. Mol. Biol.  1994, 
242, 351-363. 
[12]  Willmott, C.J.R.; Maxwell, A. A single point mutation in the DNA 
gyrase A protein greatly reduces binding of fluoroquinolones to the 
gyrase-DNA complex.  Antimicrob. Agents Chemother.  1993,  37, 
126-127. 
[13]  Jacoby, G. Mechanisms of resistance to quinolones. Clin Inf. Dis. 
2005, 41 (Suppl. 2), S120-S126. 
[14]  Morgan-Linnell, S.; Becnel-Boyd, L.; Steffen, D.; Zechiedrich, L. 
Mechanisms accounting for fluoroquinolone resistance in 
Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 
2009, 53, 235-242. 
[15]  Park, C.; Robicsek, A.; Jacoby, G.; Sahm, D.; Hooper, D. 
Prevalence in the United States of aac(6')-Ib-cr encoding a 
ciprofloxacin-modifying enzyme. Antimicrob. Agents Chemother. 
2006, 50, 3953-3955. 
[16]  Poole, K. Efflux-mediated resistance to fluoroquinolones in Gram-
negative bacteria. Antimicrob. Agents Chemother. 2000, 44, 2233-
2241. 
[17]  Poole, K. Efflux-mediated resistance to fluoroquinolones in Gram-
positive bacteria and the mycobacteria.  Antimicrob. Agents 
Chemother. 2000, 44, 2595-2599. 
[18]  Becnel-Boyd, L.; Maynard, M.; Morgan-Linnell, S.; Horton, L.; 
Sucgang, R.; Hamill, R.; Jimenez, J.; Versalovic, J.; Steffen, D.; 
Zechiedrich, L. Relationships among ciprofloxacin, gatifloxacin, 
levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant 
Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 
2009, 53, 229-234. 
[19]  Li, X.; Zhao, X.; Drlica, K. Selection of Streptococcus pneumoniae 
mutants having reduced susceptibility to levofloxacin and 
moxifloxacin. Antimicrob. Agents Chemother. 2002, 46, 522-524. 
[20]  Zhao, X.; Drlica, K. Restricting the selection of antibiotic-resistant 
mutants: measurement and potential uses of the mutant selection 
window. J. Inf. Dis. 2002, 185, 561-565. 
[21]  Champoux, J.J. DNA topoisomerases: structure, function, and 
mechanism. Annu. Rev. Biochem. 2001, 70, 369-413. 
[22]  Drlica, K.; Malik, M. Fluoroquinolones: action and resistance. 
Curr. Top. Med. Chem. 2003, 3, 1349-1364. 
[23]  Drlica, K.; Zhao, X. DNA gyrase, topoisomerase IV, and the 4-
quinolones. Microbiol. Mol. Rev. 1997, 61, 377-392. 
[24]  Heddle, J.G.; Barnard, F.; Wentzell, L.; Maxwell, A. The 
interaction of drugs with DNA gyrase: a model for the molecular 
basis of quinolone action. Nucleosides Nucleotides Nucleic Acids 
2000, 19, 1249-1264. 
[25]  Levine, C.; Hiasa, H.; Marians, K. DNA gyrase and topoisomerase 
IV: biochemical activities, physiological roles during chromosome 
replication, and drug sensitivities.  Biochim. Biophys. Acta  1998, 
1400, 29-43. 
[26]  Nitiss, J.L. Targeting DNA topoisomerase II in cancer 
chemotherapy. Nat. Rev. Cancer 2009, 9, 338-350. 
[27]  Wang, J.C. Cellular roles of DNA topoisomerases: a molecular 
perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430-440. 994    Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11  Drlica et al. 
[28]  MoraisCabral, J.H.; Jackson, A.P.; Smith, C.V.; Shikotra, N.; 
Maxwell, A.; Liddington, R.C. Crystal structure of the breakage-
reunion domain of DNA gyrase. Nature 1997, 388, 903-906. 
[29]  Berger, J.M.; Gamblin, S.J.; Harrison, S.C.; Wang, J.C. Structure 
and mechanism of DNA topoisomerase II. Nature 1996, 379, 225-
232. 
[30]  Dong, K.C.; Berger, J.M. Structural basis for gate-DNA 
recognition and bending by type IIA topoisomerases. Nature 2007, 
450, 1201-1205. 
[31]  Kampranis, S.; Maxwell, A. Conformational changes in DNA 
gyrase revealed by limited proteolysis. J. Biol. Chem. 1998, 273, 
22606-22614. 
[32]  Sindelar, G.; Zhao, X.; Liew, A.; Dong, Y.; Zhou, J.; Domagala, J.; 
Drlica, K. Mutant prevention concentration as a measure of 
fluoroquinolone potency against mycobacteria. Antimicrob. Agents 
Chemother. 2000, 44, 3337-3343. 
[33]  Laponogov, I.; Sohi, M.; Veselkov, D.; Pan, X.; Sawhney, R.; 
Thompson, A.; McAuley, K.; Fisher, L.; Sanderson, M. Structural 
insight into the quinolone-DNA cleavage complex of type IIA 
topoisomerases. Nat. Struct. Mol. Biol. 2009, Epub ahead of print. 
[34]  Barnard, F.; Maxwell, A. Interaction between DNA gyrase and 
quinolones: the effect of alanine mutations at A subunit residues 
Ser-83 and Asp-87.  Antimicrob. Agents Chemother.  2001,  45, 
1994-2000. 
[35]  Morrissey, I.; Hoshino, K.; Sato, K.; Yoshida, A.; Hayakawa, I.; 
Bures, M.; Shen, L.L. Mechanism of differential activities of 
ofloxacin enantiomers. Antimicrob. Agents Chemother. 1996, 40, 
1775-1784. 
[36]  Cambau, E.; Borden, F.; Collatz, E.; Gutmann, L. Novel gyrA point 
mutation in a strain of Escherichia coli resistant to fluoro-
quinolones but not to nalidixic acid. Antimicrob. Agents 
Chemother. 1993, 37, 1247-1252. 
[37]  Critchlow, S.E.; Maxwell, A. DNA cleavage is not required for the 
binding of quinolone drugs to the DNA gyrase-DNA complex. 
Biochemistry 1996, 35, 7387-7393. 
[38]  Marians, K.; Hiasa, H. Mechanism of quinolone action: a drug-
induced structural perturbation of the DNA precedes strand 
cleavage by topoisomerase IV.  J. Biol. Chem.  1997,  272, 9401-
9409. 
[39]  Zechiedrich, E.L.; Khodursky, A.; Bachellier, S.; Schneider, R.; 
Chen, D.; Lilley, D.; Cozzarelli, N. Roles of topoisomerases in 
maintaining steady-state DNA supercoiling in Escherichia coli. J. 
Biol. Chem. 2000, 275, 8103-8113. 
[40]  Deibler, R.; Rahmati, S.; Zechiedrich, L. Topoisomerase IV, alone, 
unknots DNA in E. coli. Genes Dev. 2001, 15, 748-761. 
[41]  Zechiedrich, E.L.; Cozzarelli, N.R. Roles of topoisomerase IV and 
DNA gyrase in DNA unlinking during replication in Escherichia 
coli. Genes Dev. 1995, 9, 2859-2869. 
[42]  Zechiedrich, E.L.; Khodursky, A.; Cozzarelli, N.R. Topoisomerase 
IV not gyrase, decatenates products of site-specific recombination 
in Escherichia coli. Genes Dev. 1997, 11, 2580-2592. 
[43]  Kampranis, S.C.; Maxwell, A. Conversion of DNA gyrase into a 
conventional type II topoisomerase.  Proc. Natl. Acad. Sci. USA 
1996, 93, 14416-14421. 
[44]  Liu, L.F.; Wang, J.C. DNA-DNA gyrase complex: the wrapping of 
DNA duplex outside the enzyme. Cell 1978, 15, 979-984. 
[45]  Corbett, K.D.; Berger, J.M. The C-terminal domain of DNA gyrase 
A adopts a DNA-bending beta-pinwheel fold. Proc. Natl. Acad. 
Sci. USA 2004, 101, 7293-7298. 
[46]  Hsieh, T.; Farh, L.; Huang, W.; Chan, N. Structure of the 
topoisomerase IV C-terminal domain: a broken b-propeller Implies 
a role as geometry facilitator in catalysis. J. Biol. Chem. 2004, 279, 
55587-55593. 
[47]  Ruthenburg, A.J.; Graybosch, D.M.; Huetsch, J.C.; Verdine, G.L. 
A superhelical spiral in the Escherichia coli DNA gyrase A C-
terminal domain imparts unidirectional supercoiling bias. J. Biol. 
Chem. 2005, 280, 26177-26184. 
[48]  Corbett, K.D.; Schoeffler, A.J.; Thomsen, N.D.; Berger, J.M. The 
structural basis for substrate specificity in DNA topoisomerase IV. 
J. Mol. Biol. 2005, 351, 545-561. 
[49]  Huang, W.M. Bacterial diversity based on type II topoisomerase 
genes. Annu. Rev. Genet. 1996, 30, 79-107. 
[50]  Ward, D.; Newton, A. Requirement of topoisomerase IV parC and 
parE geens for cell cycle progression and development regulation 
in Caulobacter crescentus. Mol. Microbiol. 1997, 26, 897-910. 
[51]  Kamlinger, V.M.; Hiasa, H. The 'GyrA-box' is required for the 
ability of DNA gyrase to wrap DNA and catalyze the supercoiling 
reaction. J. Biol. Chem. 2006, 281, 3738-3742. 
[52]  Costenaro, L.; Grossmann, J.G.; Ebel, C.; Maxwell, A. Small-angle 
X-ray scattering reveals the solution structure of the full-length 
DNA gyrase a subunit. Structure 2005, 13, 287-296. 
[53]  Kirchhausen, T.; Wang, J.C.; Harrison, S.C. DNA gyrase and its 
complexes with DNA: direct observation by electron microscopy. 
Cell 1985, 41, 933-943. 
[54]  Hiasa, H.; Shea, M. DNA gyrase-mediated wrapping of the DNA 
strand is required for the replication fork arrest by the DNA gyrase-
quinolone-DNA ternary complex. J. Biol. Chem. 2000, 275, 34780-
34786. 
[55]  Hiasa, H.; Shea, M.; Richardson, C.; Gwynn, M. Staphylococcus 
aureus gyrase-quinolone-DNA ternary complexes fail to arrest 
replication fork progression in vitro: effects of salt on the DNA 
binding mode and the catalytic activity of Staphylococcus aureus 
gyrase. J. Biol. Chem. 2003, 278, 8861-8868. 
[56]  Goss, W.; Deitz, W.; Cook, T. Mechanism of action of nalidixic 
acid on Escherichia coli. II. Inhibition of deoxyribonucleic acid 
synthesis. J. Bacteriol. 1965, 89, 1068-1074. 
[57]  Fox, M.; Smith, P. Long-term inhibition of DNA synthesis and the 
persistence of trapped topoisomerase II complexes in determining 
the toxicity of the antitumor DNA intercalators mAMSA and 
mitoxantrone. Cancer Res. 1990, 50, 5813-5918. 
[58]  Horwitz, S.B.; Chang, C.; Grollman, A. Antiviral action of 
camptothecin. Antimicrob. Agents Chemother. 1972, 2, 395-401. 
[59]  Tsao, Y.-P.; Russo, A.; Nyamuswa, G.; Silber, R.; Liu, L.F. 
Interaction between replication forks and topoisomerase I-DNA 
cleavable complexes: studies in a cell-free SV40 DNA replication 
system. Cancer Res. 1993, 53, 5908-5914. 
[60]  Khodursky, A.; Cozzarelli, N. The mechanism of inhibition of 
topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 1998, 
273, 27668-27677. 
[61]  Chen, C.-R.; Malik, M.; Snyder, M.; Drlica, K. DNA gyrase and 
topoisomerase IV on the bacterial chromosome: quinolone-induced 
DNA cleavage. J. Mol. Biol. 1996, 258, 627-637. 
[62]  Drlica, K.; Pruss, G.; Burger, R.; Franco, R.; Hsieh, L.-S.; Berger, 
B. Roles of DNA topoisomerases in bacterial chromosome 
structure and function. in The Bacterial Chromosome Drlica, K.; 
Riley, M.; Eds. American Society for Microbiology: Washington. 
1990, pp. 195-204. 
[63]  Malik, M.; Hussain, S.; Drlica, K. Effect of anaerobic growth on 
quinolone lethality with Escherichia coli.  Antimicrob. Agents 
Chemother. 2007, 51, 28-34. 
[64]  Zhao, X.; Malik, M.; Chan, N.; Drlica-Wagner, A.; Wang, J.-Y.; 
Li, X.; Drlica, K. Lethal action of quinolones with a temperature-
sensitive dnaB replication mutant of Escherichia coli. Antimicrob. 
Agents Chemother. 2006, 50, 362-364. 
[65]  Hong, G.; Kreuzer, K. An antitumor drug-induced topoisomerase 
cleavage complex blocks a bacteriophage T4 replication fork in 
vivo. Mol. Cell Biol. 2000, 20, 594-603. 
[66]  Lucas, I.; Germe, T.; Chevrier-Miller, M.; Hyrien, O. 
Topoisomerase II can unlink replicating DNA by precatenane 
removal. EMBO J. 2001, 20, 6509-6519. 
[67]  Li, T.K.; Liu, L.F. Tumor cell death induced by topoisomerase-
targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 53-77. 
[68]  Maxwell, A. DNA gyrase as a drug target. Biochem. Soc. Trans. 
1999, 27, 48-53. 
[69]  Wistermann, A.M.; Osheroff, N. Stabilization of eukaryotic 
topoisomerase II-DNA cleavage complexes. Curr. Top. Med. 
Chem. 2003, 3, 321-338. 
[70]  Fournier, B.; Zhao, X.; Lu, T.; Drlica, K.; Hooper, D. Selective 
targeting of topoisomerase IV and DNA gyrase in Staphylococcus 
aureus: different patterns of quinolone-induced inhibition of DNA 
synthesis. Antimicrob. Agents Chemother. 2000, 44, 2160-2165. 
[71]  Pfeiffer, E.; Hiasa, H. Replacement of ParC a4 helix with that of 
GyrA increases the stability and cytotoxicity of topoisomerase IV-
quinolone-DNA ternary complexes.  Antimicrob. Agents 
Chemother. 2004, 48, 608-611. 
[72]  Strahilevitz, J.; Robicsek, A.; Hooper, D. Role of the extended 
alpha4 domain of Staphylococcus aureus gyrase A protein in 
determining low sensitivity to quinolones.  Antimicrob. Agents 
Chemother. 2006, 50, 600-606. Quinolones: action and resistance updated  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11     995 
[73]  Bandele, O.J.; Osheroff, N. The efficacy of topoisomerase II-
targeted anticancer agents reflects the persistence of drug-induced 
cleavage complexes in cells. Biochemistry 2008, 47, 11900-11908. 
[74]  Gudas, L.J.; Pardee, A.B. DNA synthesis inhibition and the 
induction of protein X in Eschericia coli. J. Mol. Biol. 1976, 101, 
459-477. 
[75]  Jeong, K.S.; Xie, Y.; Hiasa, H.; Khodursky, A. Analysis of 
Pleiotropic Transcriptional Profiles: A Case Study of DNA Gyrase 
Inhibition. PLOS Genet. 2006, 2, e152. 
[76]  Oppegard, L.; Hamann, B.; Streck, K.; Ellis, K.; Fieldler, H.; 
Khodursky, A.; Hiasa, H. In vivo and in vitro patterns of the 
activity of simocyclinone D8, an angucyclineone antibiotic from 
Streptomyces antibioticus.  Antimicrob. Agents Chemother.  2009, 
53, 2110-2119. 
[77]  Sangurdekar, D.; Srienc, F.; Khodursky, A. A classification based 
framework for quantitative description of large-scale microarray 
data. Genome Biol. 2006, 7, R32. 
[78]  Hong, G.; Kreuzer, K. Endonuclease cleavage of blocked 
replication forks: an indirect pathway of DNA damage from 
antitumor drug-topoisomerase complexes.  Proc. Natl. Acad. Sci. 
USA 2003, 100, 5046-5051. 
[79]  Pohlhaus, J.; Kreuzer, K.N. Norfloxacin-induced DNA gyrase 
cleavage complexes block Escherichia coli replication forks, 
causing double-stranded breaks in vivo. Mol. Microbiol. 2005, 56, 
1416-1429. 
[80]  Cox, M.; Goodman, M.; Kreuzer, K.; Sherratt, D.; Sandler, S.; 
Marians, K. The importance of repairing stalled replication forks. 
Nature 2000, 404, 37-41. 
[81]  Grompone, M.; Flores, G.; Bidnenko, V. Multiple pathways 
process stalled replication forks. Proc. Natl. Acad. Sci. USA 2004, 
101, 12783-12788. 
[82]  Heller, R.C.; Marians, K.J. Replisome assembly and the direct 
restart of stalled replication forks. Nat. Rev. Mol. Cell Biol. 2006, 7, 
932-943. 
[83]  McGlynn, P.; Lloyd, R.G. Recombinational repair and restart of 
damaged replication forks. Nat. Rev. Mol. Cell Biol. 2002, 3, 859-
870. 
[84]  Shea, M.; Hiasa, H. The RuvAB branch migration complex can 
displace topoisomerase IV-quinolone-DNA ternary complexes. J. 
Biol. Chem. 2003, 278, 48485-48490. 
[85]  Malik, M.; Drlica, K. Moxifloxacin lethality with Mycobacterium 
tuberculosis in the presence and absence of chloramphenicol. 
Antimicrob. Agents Chemother. 2006, 50, 2842-2844. 
[86]  Hussain, S.; Malik, M.; Shi, L.; Gennaro, M.; Drlica, K. In vitro 
model of mycobacterial growth arrest using nitric oxide with 
limited air. Antimicrob. Agents Chemother. 2009, 53, 157-161. 
[87]  Krasin, F.; Hutchinson, F. Repair of DNA double-strand breaks in 
Escherichia coli, which requires recA function and the presence of 
a duplicate genome. J. Mol. Biol. 1977, 116, 81-98. 
[88]  Malik, M.; Zhao, X.; Drlica, K. Lethal fragmentation of bacterial 
chromosomes mediated by DNA gyrase and quinolones.  Mol. 
Microbiol. 2006, 61, 810-825. 
[89]  Ikeda, H.; Aoki, K.; Naito, A. Illegitimate recombination mediated 
in vitro by DNA gyrase of Escherichia coli: structure of 
recombinant DNA molecules. Proc. Natl. Acad. Sci. USA 1982, 79, 
3724-3728. 
[90]  Ikeda, H.; Kawasaki, I.; Gellert, M. Mechanism of illegitimate 
recombination: common sites for recombination and cleavage 
mediated by E. coli DNA gyrase. Mol. Gen. Genet. 1984, 196, 546-
549. 
[91]  Dwyer, D.; Kohanski, M.; Hayete, B.; Collins, J. Gyrase inhibitors 
induce an oxidative damage cellular death pathway in Escherichia 
coli. Mol. Syst. Biol. 2007, 3, 91. 
[92]  Kohanski, M.; Dwyer, D.; Hayete, B.; Lawrence, C.; Collins, J. A 
common mechanism of cellular death induced by bactericidal 
antibiotics. Cell 2007, 130, 797-810. 
[93]  Wang, X.; Zhao, X. Contribution of oxidative damage to 
antimicrobial lethality.  Antimicrob. Agents Chemother.  2009,  53, 
1395-1402. 
[94]  Wang, X.; Zhao, X.; Malik, M.; Drlica, K. Reactive oxygen species 
are responsible for chloramphenicol-sensitive lethality of 
quinolones. unpublished observations. 
[95]  Tsilibaris, V.; Maenhaut-Michel, G.; VanMelderen, L. Biological 
roles of the Lon ATP-dependent protease. Res. Microbiol. 2006, 
157, 701-713. 
[96]  Chung, C.; Goldberg, A. DNA stimulates ATP-dependent 
proteolysis and protein-dependent ATPase activity of protease La 
from Escherichia coli. Proc. Natl. Acad. Sci. USA 1982, 79, 795-
799. 
[97]  Lee, I.; Suzuki, C.K. Functional mechanics of the ATP-dependent 
Lon protease: lessons from endogenous protein and synthetic 
peptide substrates. Biochim. Biophys. Acta 2008, 1784, 727-735. 
[98]  Nomura, K.; Kato, J.; Takiguchi, N.; Ohtake, H.; Kuroda, A. 
Effects of inorganic phosphate on the proteolytic and DNA-binding 
activities of Lon in Escherichia coli.  J. Biol. Chem.  2004,  279, 
34406-34410. 
[99]  Crumplin, G.C.; Smith J.T. Nalidixic acid: an antibacterial paradox. 
Antimicrob. Agents Chemother. 1975, 8, 251-261. 
[100]  Malik, M.; Capecci, J.; Drlica, K. Lon protease is essential for 
paradoxical survival of Escherichia coli when exposed to high 
concentrations of quinolone. Antimicrob. Agents Chemother. 2009, 
53, 3103-3105. 
[101]  Pan, X.-S.; Ambler, J.; Mehtar, S.; Fisher, L.M. Involvement of 
topoisomerase IV and DNA gyrase as ciprofloxacin targets in 
Streptococcus pneumoniae. Antimicrob. Agents Chemother. 1996, 
40, 2321-2326. 
[102]  Zhou, J.; Dong, Y.; Zhao, X.; Lee, S.; Amin, A.; Ramaswamy, S.; 
Domagala, J.; Musser, J.M.; Drlica, K. Selection of antibiotic 
resistant bacterial mutants: allelic diversity among fluoroquinolone-
resistant mutations. J. Inf. Dis. 2000, 182, 517-525. 
[103]  Ferrero, L.; Cameron, B.; Manse, B.; Lagneaux, D.; Crouzet, J.; 
Famechon, A.; Blanche, F. Cloning and primary structure of 
Staphylococcus aureus DNA topoisomerase IV: a primary target of 
fluoroquinolones. Mol. Microbiol. 1994, 13, 641-653. 
[104]  Kern, W.; Oethinger, M.; Jellen-Ritter, A.; Levy, S. Non-target 
gene mutations in the development of fluoroquinolone resistance in 
Escherichia coli.  Antimicrob. Agents Chemother.  2000,  44, 814-
820. 
[105]  Li, X.; Mariano, N.; Rahal, J.J.; Urban, C.M.; Drlica, K. 
Quinolone-resistant  Haemophilus influenzae: determination of 
mutant selection window for ciprofloxacin, garenoxacin, 
levofloxacin, and moxifloxacin.  Antimicrob. Agents Chemother. 
2004, 48, 4460-4462. 
[106]  Bast D.; Low D.; Duncan C.; Kilburn L.; Mandell L.; Davidson R.; 
deAzavedo, J. Fluoroquinolone resistance in clinical isolates of 
Streptococcus pneumoniae: contributions of type II topoisomerase 
mutations and efflux on levels of resistance.  Antimicrob. Agents 
Chemother. 2000, 44, 3049-3054. 
[107]  Acar, J.; Goldstein, F. Trends in bacterial resistance to 
fluoroquinolones. Clin. Infect. Dis. 1997, 24, S67-S73. 
[108]  Johnson, A.P. Antibiotic resistance among clinically important 
Gram-positive bacteria in the UK. J. Hosp. Infect. 1998, 40, 17-26. 
[109]  Sieradzki, K.; Roberts, R.; Haber, S.; Tomasz, A. The development 
of vancomycin resistance in a patient with methicillin-resistant 
Staphylococcus aureus infection. N. Engl. J. Med. 1999, 340, 517-
523. 
[110]  Dong, Y.; Zhao, X.; Domagala, J.; Drlica, K. Effect of fluoro-
quinolone concentration on selection of resistant mutants of 
Mycobacterium bovis BCG and Staphylococcus aureus. 
Antimicrob. Agents Chemother. 1999, 43, 1756-1758. 
[111]  Quinn, B.; Hussain, S.; Malik, M.; Drlica, K.; Zhao, X. 
Daptomycin inoculum effects and mutant prevention concentration 
with Staphylococcus aureus. J. Antimicrob. Chemother. 2007, 60, 
1380-1383. 
[112]  Campion, J.; Chung, P.; McNamara, P.; Titlow, W.; Evans, M. 
Pharmacodynamic modeling of the evolution of levofloxacin 
resistance in Staphylococcus aureus.  Antimicrob. Agents 
Chemother. 2005, 49, 2189-2199. 
[113]  Campion, J.; McNamara, P.; Evans, M. Pharmacodynamic 
modeling of ciprofloxacin resistance in Staphylococcus aureus. 
Antimicrob. Agents Chemother. 2005, 49, 209-219. 
[114]  Campion, J.; McNamara, P.; Evans, M.E. Evolution of 
ciprofloxacin-resistant  Staphylococcus aureus in in vitro 
pharmacokinetic environments.  Antimicrob. Agents Chemother. 
2004, 48, 4733-4744. 
[115]  Firsov, A.; Smirnova, M.; Lubenko, I.; Vostrov, S.; Portnoy, Y.; 
Zinner, S. Testing the mutant selection window hypothesis with 
Staphylococcus aureus exposed to daptomycin and vancomycin in 
an in vitro dynamic model. J. Antimicrob. Chemother. 2006, 58, 
1185-1192. 996    Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11  Drlica et al. 
[116]  Firsov, A.; Vostrov, S.; Lubenko, I.; Arzamastsev, A.; Portnoy, Y.; 
Zinner, S. ABT492 and levofloxacin: comparison of their 
pharmacodynamics and their abilities to prevent the selection of 
resistant Staphylococcus aureus in an in vitro dynamic model. J. 
Antimicrob. Chemother. 2004, 54, 178-186. 
[117]  Firsov, A.; Vostrov, S.; Lubenko, I.; Drlica, K.; Portnoy, Y.; 
Zinner, S. In vitro pharmacodynamic evaluation of the mutant 
selection window hypothesis: four fluoroquinolones against 
Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47, 
1604-1613. 
[118]  Firsov, A.; Vostrov, S.; Lubenko, I.; Portnoy, Y.; Zinner, S. 
Prevention of the selection of resistant Staphylococcus aureus by 
moxifloxacin plus doxycycline in an in vitro dynamic model: an 
additive effect of the combination. Int. J. Antimicrob. Agents 2004, 
23, 451-456. 
[119]  Firsov, A.; Vostrov, S.; Lubenko, I.; Zinner, S.; Portnoy, Y. 
Concentration-dependent changes in the susceptibility and killing 
of  Staphylococcus aureus in an in vitro dynamic model that 
simulates normal and impaired gatifloxacin elimination.  Int. J. 
Antimicrob. Agents 2004, 23, 60-66. 
[120]  Olofsson, S.; Marcusson, L.; Komp-Lindgren, P.; Hughes, D.; 
Cars, O. Selection of ciprofloxacin resistance in Escherichia coli in 
an  in vitro kinetic model: relation between drug exposure and 
mutant prevention concentration. J. Antimicrob. Chemother. 2006, 
57, 1116-1121. 
[121]  Olofsson, S.; Marcusson, L.; Stomback, A.; Hughes, D.; Cars, O. 
Dose-related selection of fluoroquinolone-resistant Escherichia 
coli. J. Antimicrob. Chemother. 2007, 60, 795-801. 
[122]  Cui, J.; Liu, Y.; Wang, R.; Tong, W.; Drlica, K.; Zhao, X. The 
mutant selection window demonstrated in rabbits infected with 
Staphylococcus aureus. J. Inf. Dis. 2006, 194, 1601-1608. 
[123]  Ambrose, P.; Zoe-Powers, A.; Russo, R.; Jones, D.; Owens, R., 
Utilizing  pharmacodynamics and pharmacoeconomics in clinical 
and formulary decision making, in Antimicrobial pharmaco-
dynamics in theory and clinical practice, Nightingale C, Murakawa 
T, and Ambrose P, Editors. 2002, Marcel Dekker: New York. p. 
385-409. 
[124]  Zhao, X.; Drlica, K. Restricting the selection of antibiotic-resistant 
mutants: a general strategy derived from fluoroquinolone studies. 
Clin. Inf. Dis. 2001, 33 (Suppl 3), S147-S156. 
[125]  Stratton, C. Dead bugs don't mutate: susceptibility issues in the 
emergence of bacterial resistance. Emerg. Infect. Dis. 2003, 9, 10-
16. 
[126]  Liu, Y.; Cui, J.; Wang, R.; Wang, X.; Drlica, K.; Zhao, X. 
Selection of rifampicin-resistant Staphylococcus aureus during 
tuberculosis therapy: concurrent bacterial eradication and 
acquisition of resistance.  J. Antimicrob. Chemother.  2005,  56, 
1172-1175. 
[127]  Bejar, S.; Bouche, J. The spacing of Escherichia coli DNA gyrase 
sites cleaved in vivo by treatment with oxolinic acid and sodium 
dodecyl sulfate. Biochimie 1984, 66, 693-700. 
[128]  Fukuda, H.; Kishii, R.; Takei, M.; Hosaka, M. Contributions of the 
8-methoxy group of gatifloxacin to resistance selectivity, target 
preference, and antibacterial activity against Streptococcus 
pneumoniae. Antimicrob. Agents Chemother. 2001, 45, 1649-1653. 
[129]  Craig, W. Pharmacokinetic/pharmacodynamic parameters: 
rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 
1998, 26, 1-12. 
[130]  Schentag, J. Antimicrobial action and pharmacokinetics/ 
pharmacodynamics: the use of AUIC to improve efficacy and avoid 
resistance. J. Chemother. 1999, 11, 426-439. 
[131]  Drlica, K.; Zhao, X. Mutant selection window hypothesis updated. 
Clin. Inf. Dis. 2007, 44, 681-688. 
[132]  Zhao, X.; Drlica, K. A unified anti-mutant dosing strategy.  J. 
Antimicrob. Chemother. 2008, 62, 434-436. 
[133]  Ambrose, P.; Grasela, D. The use of Monte Carlo simulation to 
examine pharmacodynamic variance of drugs: fluoroquinolone 
pharmcodynamics against Streptococcus pneumoniae.  Diagn. 
Microbiol. Infect. Dis. 2000, 38, 151-157. 
[134]  Preston, S.; Drusano, G.; Berman, A.; Fowler, C.; Chow, A.; 
Dornseif, B.; Reichi, V.; Natarajan, J.; Corrado, M. Pharmaco-
dyamics of levofloxacin: a new paradigm for early clinical trials. 
JAMA 1998, 279, 125-129. 
[135]  Blondeau, J.; Zhao, X.; Hansen, G.; Drlica, K. Mutant prevention 
concentrations (MPC) for fluoroquinolones with clinical isolates of 
Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2001, 
45, 433-438. 
[136]  Hansen, G.; Zhao, X.; Drlica, K.; Blondeau, J. Mutant prevention 
concentration for ciprofloxacin and levofloxacin with Pseudo-
monas aeruginosa. Int. J. Antimicrob. Agents 2006, 27, 120-124. 
[137]  Metzler, K.; Hansen, G.; Hedlin, P.; Harding, E.; Drlica, K.; 
Blondeau, J. Comparison of minimal inhibitory and mutant 
prevention concentrations of 4 fluoroquinolones: methicillin-
susceptible and -resistant Staphylococcus aureus.  Int. J. 
Antimicrob. Agents 2004, 24, 161-167. 
[138]  Drlica, K.; Zhao, X.; Blondeau, J.; Hesje, C. Low correlation 
between minimal inhibitory concentration (MIC) and mutant 
prevention concentration (MPC).  Antimicrob. Agents Chemother. 
2006, 50, 403-404. 
[139]  Marcusson, L.; Olofsson, S.; Lindgren, P.; Cars, O.; Hughes, D. 
Mutant prevention concentration of ciprofloxacin for urinary tract 
infection isolates of Escherichia coli.  J. Antimicrob. Chemother. 
2005, 55, 938-943. 
[140]  Cirz, R.; Chin, J.; Andes, D.; Crecy-Lagard, V.; Craig, W.; 
Romesberg, F.E. Inhibition of mutation and combating the 
evolution of antibiotic resistance. Plos Biol. 2005, 3, 1024-1033. 
[141]  Cirz, R.; Romesberg, F. Induction and inhibition of ciprofloxacin 
resistance-conferring mutations in hypermutator bacteria. 
Antimicrob. Agents Chemother. 2006, 50, 220-225. 
[142]  Bird, P.; Ellsworth, E.; Nguyen, D.; Sanchez, J.; Showalter, H.; 
Singh, R.; Stier, M.; Tran, T.; Watson, B.; Yip, J. 3-
aminoquinazolin-2,4-dione antibacterial agents. Warner Lambert 
Company LLC. United States Patent 20067094780B1. 
[143]  Ellsworth, E.; Tran, T.; Showalter, H.H.; Sanchez, J.; Watson, B.; 
Stier, M.; Domagala, J.; Gracheck, S.; Joannides, E.; Shapiro, M.; 
Dunham, S.; Hanna, D.; Huband, M.; Gage, J.; Bronstein, J.; Liu, 
J.; Nguyen, D.; Singh, R. 3-aminoquinazolinediones as a new class 
of antibacterial agents demonstrating excellent antibacterial activity 
against wild-type and multidrug resistant organisms. J. Med. Chem. 
2006, 49, 6435-6438. 
[144]  Huband, M.D.; Cohen, M.A.; Zurack, M.; Hanna, D.L.; Skerlos, 
L.A.; Sulavik, M.C.; Gibson, G.W.; Gage, J.W.; Ellsworth, E.; 
Stier, M.A.; Gracheck, S.J. In vitro and in vivo activities of PD 
0305970 and PD 0326448, new bacterial gyrase/topoisomerase 
inhibitors with potent antibacterial activities versus multidrug-
resistant gram-positive and fastidious organism groups. Antimicrob. 
Agents Chemother. 2007, 51, 1191-1201. 
[145]  Hutchings, K.M.; Tran, T.P.; Ellsworth, E.L.; Watson, B.M.; 
Sanchez, J.P.; Showalter, H.D.; Stier, M.A.; Shapiro, M.; 
Joannides, E.T.; Huband, M.; Nguyen, D.Q.; Maiti, S.; Li, T.; 
Tailor, J.; Thomas, G.; Ha, C.; Singh, R. Synthesis and antibacterial 
activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg. 
Med. Chem. Lett. 2008, 18. 
[146]  Tran, T.; Ellsworth, E.; Sanchez, J.; Watson, B.; Stier, M.; 
Showalter, H.; Domagala, J.; Shapiro, M.; Joannides, E.; Gracheck, 
S.; Nguyen, D.; Bird, P.; Yip, J.; Sharadendu, A.; Ha, C.; 
Ramezani, S.; Wu, X.; Singh, R. Structure-activity relationships of 
3-aminoquinazoline-diones, a new class of bacterial type-2 
topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg. Med. 
Chem. Lett. 2007, 17, 1312-1320. 
[147]  Ellsworth, E.; Hutchings, K.; Nguyen, B.; Singh, R.; Showalter, H., 
Antibacterial agents. Warner-Lambert Company. United  States 
Patent 2005 6,864,259 B2. p. 124. 
[148]  Rosen, J.D.; German, N.; Kerns, R.J. Efficient synthesis of the 2-
amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-
c]pyrimidine-1,3-dione core ring system. Tetrahedron Lett. 2009, 
50, 785-789. 
[149]  German, N.; Malik, M.; Rosen, J.; Drlica, K.; Kerns, R. Use of 
gyrase resistance mutants to guide selection of 8-methoxy-
quinazoline-2,4-diones. Antimicrob. Agents Chemother. 2008, 52, 
3915-3921. 
[150]  Fisher, L.l.; Heaton, V.J. Dual activity of fluoroquinolones against 
Streptococcus pneumoniae.  J. Antimicrob. Chemother.  2003,  51, 
463-464. 
[151]  Ince, D.; Zhang, X.; Silver, L.C.; Hooper, D.C. Dual targeting of 
DNA gyrase and topoisomerase IV: target interactions of gareno-
xacin (BMS-284756, T-3811ME), a new desfluoroquinolone. 
Antimicrob. Agents Chemother. 2002, 46, 3370-3380. 
[152]  Okumura, R.; Hirata, T.; Onodera, Y.; Hoshino, K.; Otani, T.; 
Yamamoto, T. Dual-targeting properties of the 3-aminopyrrolidyl 
quinolones, DC-159a and sitafloxacin, against DNA gyrase and Quinolones: action and resistance updated  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11     997 
topoisomerase IV: contribution to reducing in vitro emergence of 
quinolone-resistant  Streptococcus pneumoniae.  J. Antimicrob. 
Chemother. 2008, 62, 98-104. 
[153]  Strahilevitz, J.; Hooper, D.C. Dual targeting of topoisomerase IV 
and gyrase to reduce mutant selection: direct testing of the 
paradigm by using WCK-1734, a new fluoroquinolone, and 
ciprofloxacin.  Antimicrob. Agents Chemother.  2005,  49, 1949-
1956. 
[154]  Takei, M.; Fukuda, H.; Kishi, R.; Hosaka, M. Target preference of 
15 quinolones against Staphylococcus aureus, based on 
antibacterial activities and target inhibition.  Antimicrob. Agents 
Chemother. 2001, 45, 3544-3547. 
[155]  Cheng, J.; Thanassi, J.A.; Thoma, C.L.; Bradbury, B.J.; Deshpande, 
M.; Pucci, M.J. Dual targeting of DNA gyrase and topoisomerase 
iv: target interactions of heteroaryl isothiazolones in 
Staphylococcus aureus. Antimicrob. Agents Chemother. 2007, 51, 
2445-2453. 
[156]  Bremner, J.; Ambrus, J.; Samosom, S. Dual action-based 
approaches to antibacterial agents.  Curr. Med. Chem.  2007,  14, 
1459-1477. 
[157]  Silver, L. Multi-targeting by monotherapeutic antibacterials. Nat. 
Rev. Drug Discov. 2007, 6, 41-55. 
[158]  Robertson, G.; Bonventre, E.; Doyle, T.; Du, Q.; Duncan, L.; 
Morris, T.; Roche, E.; Yan, D.; Lynch, A. In vitro evaluation of 
CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: 
microbiology profiling studies with staphylococci and streptococci. 
Antimicrob. Agents Chemother. 2008, 52, 2324-2334. 
[159]  Robertson, G.; Bonventre, E.; Doyle, T.; Du, Q.; Duncan, L.; 
Morris, T.; Roche, E.; Yan, D.; Lynch, A. In vitro evaluation of 
CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies 
of the mode of action in Staphylococcus  aureus.  Antimicrob. 
Agents Chemother. 2008, 52, 2313-2323. 
[160]  Gordeev, M.; Hackbarth, C.; Barbachyn, M.R.; L.S. Banitt Gage, 
J.R.; Luehr, G.W.; Gomez, M.; Trias, J.; Morin, S.E.; Zurenko, 
G.E.; Parker, C.N.; Evans, J.M.; White, R.J.; Patel, D.V. Novel 
oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. 
Chem. Lett. 2003, 13, 4213-4216. 
[161]  Alonso, G.; Baptista, K.; Ngo, T.; Taylor, D. Transcriptional 
organization of the temperature-sensitive transfer system from the 
IncHI1 plasmid R27. Microbiology 2005, 35, 3563-3573. 
[162]  Luo, H.; Wan, K.; Wang, H. High-frequency conjugation system 
facilitates biofilm formation and pAMb1 transmission by 
Lactococcus lactis. Appl. Environ. Microbiol. 2005, 71, 2970-2978. 
[163]  Oppegaard, H.; Steinum, T.; Wasteson, Y. Horizontal transfer of a 
multi-drug resistance plasmid between coliform bacteria of human 
and bovine origin in a farm environment. Appl. Environ. Microbiol. 
2001, 67, 3732-3734. 
[164]  Martinez-Martinez, L.; Pascual, A.; Jacoby, G. Quinolone 
resistance from a transferrable plasmid. Lancet 1998, 351, 797-799. 
[165]  Robicsek, A.; Strahilevitz, J.; Jacoby, G.; Macielag, M.; Abbanat, 
d.; Park, C.; Bush, K.; Hooper, D. Fluoroquinolone-modifying 
enzyme: a new adaptation of a common aminoglycoside 
acetyltransferase. Nat. Med. 2006, 12, 83-88. 
[166]  Tolmasky, M.; Roberts, M.; Woloj, M.; Crosa, J. Molecular 
cloning of amikacin resistance determinants from a Klebsiella 
pneumoniae plasmid. Antimicrob. Agents Chemother.  1986,  30, 
315-320. 
[167]  Yamane, K.; Wachino, J.; Suzuki, S.; Arakawa, Y. Plasmid-
mediated qepA gene among Escherichia coli clinical isolates from 
Japan. Antimicrob. Agents Chemother. 2008, 52, 1564-1566. 
[168]  Périchon, B.; Courvalin, P.; Galimand, M. Transferable resistance 
to aminoglycosides by methylation of G1405 in 16S rRNA and to 
hydrophilic fluoroquinolones by QepA-mediated efflux in 
Escherichia coli. Antimicrob. Agents Chemother. 2007, 51, 2464-
2469. 
[169]  Jacoby, G.; Walsh, K.; Mills, D.; Moreno, F. A new plasmid-
mediated gene for quinolone resistance. in Forty-fourth Inter-
science Conference on Antimicrobial Agents and Chemotherapy. 
American Society for Microbiology, Washington DC, 2004. 
[170]  Hata, M.; Suzuki, M.; Matsumoto, M.; Takahashi, M.; Sato, K.; 
Ibe, S.; Sakae, K. Cloning of a novel gene for quinolone resistance 
from a transferable plasmid in Shigella flexneri 2b. Antimicrob. 
Agents Chemother. 2005, 49, 801-803. 
[171]  Tran J.; Jacoby G. The mechanism of plasmid-mediated quinolone 
resistance. Proc. Natl. Acad. Sci. USA 2002, 99, 5638-5642. 
[172]  Vetting, M.; Hegde, S.; Fajardo, J.; Fiser, A.; Roderick, S.; Takiff, 
T.; Blanchard, J. Pentapeptide repeat proteins. Biochemistry 2006, 
45, 1-10. 
[173]  Hegde, S.; Vetting, M.; Roderick, S.; Mitchenall, L.; Maxwell, A.; 
Takiff, H.; Blanchard, J. A fluoroquinolone resistance protein from 
Mycobacterium tuberculosis that mimics DNA. Science 2005, 308, 
1480-1483. 
[174]  Montero, C.; Mateu, G.; Rodriguez, R.; Takiff, H. Intrinsic 
resistance of Mycobacterium smegmatis to fluoroquinolones may 
be influenced by new pentapeptide protein MfpA.  Antimicrob. 
Agents Chemother. 2001, 45, 3387-3392. 
[175]  Tran, J.; Jacoby, G.; Hooper, D. Interaction of the plasmid-encoded 
quinlone resistance protein QnrA with Escherichia coli 
topoisomerase IV. Antimicrob. Agents Chemother. 2005, 49, 3050-
3052. 
[176]  Tran, J.; Jacoby, G.; Hooper, D. Interaction of the plasmid-encoded 
quinolone resistance protein Qnr with Escherichia coli DNA 
gyrase. Antimicrob. Agents Chemother. 2005, 49, 118-125. 
[177]  Nordmann, P.; Poirel, L. Emergence of plasmid-mediated 
resistance to quinolones in Enterobacteriaceae.  J. Antimicrob. 
Chemother. 2005, 56, 463-469. 
[178]  Gay, K.; Robicsek, A.; Strahilevitz, J.; Park, C.; Jacoby, G.; 
Barrett, T.; Medalla, F.; Chiller, T.; Hooper, D. Plasmid-mediated 
quinolone resistance in non-Typhi serotypes of Salmonella 
enterica. Clin. Inf. Dis. 2006, 43, 297-304. 
[179]  Li, X. Quinolone resistance in bacteria: emphasis on plasmid-
mediated mechanisms. Int. J. Antimicrob. Agents 2005, 25, 453-
463. 
[180]  Park, Y.; Yu, J.; Lee, S.; Oh, E.; Woo, G. Prevalence and diversity 
of  qnr alleles in AmpC-producing Enterobacter cloacae, 
Enterobacter aerogenes,  Citrobacter freundii and Serratia 
marcescens: a multicentre study from Korea. J. Antimicrob. 
Chemother. 2007, 60, 868-871. 
[181]  Wang, M.; Sahm, D.; Jacoby, G.; Hooper, D. Emerging plasmid-
mediated quinolone resistance associated with the qnr gene in 
Klebsiella pneumoniae clinical isolates in the United States. 
Antimicrob. Agents Chemother. 2004, 48, 1295-1299. 
[182]  Munshi, M.; Sack, D.; Haider, K.; Ahmed, Z.; Rahaman, M.; 
Morshed, M. Plasmid-mediated resistance to nalidixic acid in 
Shigella dysenteriae type 1. Lancet 1987, 2(8556), 419-4221. 
[183]  Wang, A.; Yang, Y.; Lu, Q.; Wang, Y.; Chen, Y.; Deng, L.; Ding, 
H.; Deng, Q.; Zhang, H.; Wang, C.; Liu, L.; Xu, X.; Wang, L.; 
Shen, X. Presence of qnr gene in Escherichia coli and Klebsiella 
pneumoniae resistant to ciprofloxacin isolated from pediatric 
patients in China. BMC Microbiol. 2008, 8, 68. 
[184]  Wang, M.; Tran, J.; Jacoby, G.; Zhang, Y.; Wang, F.; Hooper, D. 
Plasmid-mediated quinolone resistance in clinical isolates of 
Escherichia coli from Shanghai, China.  Antimicrob. Agents 
Chemother. 2003, 47, 2242-2248. 
[185]  Yang, H.; Chen, H.; Yang, Q.; Chen, M.; Wang, H. High 
prevalence of plasmid-mediated quinolone resistance genes qnr and 
aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine 
teaching hospitals in China. Antimicrob. Agents Chemother. 2008, 
52, 4268-4273. 
[186]  Poirel, L.; Leviandier, C.; Nordmann, P. Prevalence and genetic 
analysis of plasmid-mediated quinolone resistance determinants 
QnrA and QnrS in Enterobacteriaceae isolates from a French 
university hospital. Antimicrob. Agents Chemother. 2006, 50, 3992-
3997. 
[187]  Jonas, D.; Biehler, K.; Hartung, D.; Spitzmüller, B.; Daschner, F. 
Plasmid-mediated quinolone resistance in isolates obtained in 
German intensive care units. Antimicrob. Agents Chemother. 2005, 
49, 773-775. 
[188]  Wu, J.; Ko, W.; Tsai, S.; Yan, J. Prevalence of plasmid-mediated 
quinolone resistance determinants QnrA, QnrB, and QnrS among 
clinical isolates of Enterobacter cloacae in a Taiwanese hospital. 
Antimicrob. Agents Chemother. 2007, 51, 1223-1227. 
[189]  Poirel, L.; VanDeLoo, M.; Mammeri, H.; Nordmann, P. 
Association of plasmid-mediated quinolone resistance with 
extended-spectrum beta-lactamase VEB-1. Antimicrob. Agents 
Chemother. 2005, 49, 3091-3094. 
[190]  Nazic, H.; Poirel, L.; Nordmann, P. Further identification of 
plasmid-mediated quinolone resistance determinant in 
Enterobacteriaceae in Turkey. Antimicrob. Agents Chemother. 
2005, 49, 2146-2147. 998    Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 11  Drlica et al. 
[191]  Corkill, J.; Anson, J.; Hart, C. High prevalence of the plasmid-
mediated quinolone resistance determinant qnrA in multidrug-
resistant Enterobacteriaceae from blood cultures in Liverpool, UK. 
J. Antimicrob. Chemother. 2005, 56, 1115-1117. 
[192]  Robicsek, A.; Strahilevitz, J.; Sahm, D.; Jacoby, G.; Hooper, D. qnr 
prevalence in ceftazidime-resistant Enterobacteriaceae isolates 
from the United States. Antimicrob. Agents Chemother. 2006, 50, 
2872-2874. 
[193]  Robicsek, A.; Jacoby, G.; Hooper, D. The worldwide emergence of 
plasmid-mediated quinolone resistance. Lancet Infect. Dis. 2006, 6, 
629-640. 
[194]  Fihman, V.; Lartigue, M.; Jacquier, H.; Meunier, F.; Schnepf, N.; 
Raskine, L.; Riahi, J.; Pors, M.S.-l.; Berçot, B. Appearance of 
aac(6')-Ib-cr gene among extended-spectrum beta-lactamase-
producing Enterobacteriaceae in a French hospital. J. Infect. 2008, 
56, 454-459. 
[195]  Cordeiro, N.; Robino, L.; Medina, J.; Seija, V.; Bado, I.; García, 
V.; Berro, M.; Pontet, J.; López, L.; Bazet, C.; Rieppi, G.; Gutkind, 
G.; Ayala, J.; Vignoli, R. Ciprofloxacin-resistant enterobacteria 
harboring the aac(6')-Ib-cr variant isolated from feces of inpatients 
in an intensive care unit in Uruguay. Antimicrob. Agents 
Chemother. 2008, 52, 806-807. 
[196]  Cattoir, V.; Poirel, L.; Nordmann, P. Plasmid-mediated quinolone 
resistance pump QepA2 in an Escherichia coli isolate from France. 
Antimicrob. Agents Chemother. 2008, 52, 3801-3804. 
[197]  Kampranis, S.; Maxwell, A. The DNA gyrase-quinolone complex, 
ATP hydrolysis and the mechanism of DNA cleavage.  J. Biol. 
Chem. 1998, 173, 22615-22626. 
[198]  Boyd, L.B.; Atmar, R.; Randall, G.; Hamill, R.; Steffen, D.; 
Zechiedrich, L. Increased fluoroquinolone resistance with time in 
Escherichia coli from >17,000 patients at a large county hospital as 
a function of culture site, age, sex, and location. BMC Inf. Dis. 
2008, 8, 4. 
[199]  Morris, S.; Richardson, S.; Sauve, L.; Ford-Jones, E.; Jamieson, F. 
Increasing fluoroquinolone resistance in Salmonella typhi in 
Ontario, 2002-2007. Am. J. Trop. Med. Hyg. 2009, 80, 1012-1013. 
[200]  O'Connor, J.; Johnson, S.; Gerding, D. Clostridium difficile 
infection caused by the epidemic BI/NAP1/027 strain. 
Gastroenterology 2009, 136, 1913-1924. 
 
 
Received July 30, 2009        Accepted July 30, 2009 
 
 
 